Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site.

# SpanishDrug Discovery Network

## Sitemaps

- [XML Sitemap](https://www.sddn.es/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [A Closer Look at Gijs Jochems](https://www.sddn.es/a-closer-look-at-gijs-jochems/) - We’re excited to feature an interview with Gijs Jochems, who recently retired as General Director of Promega, Spain. Gijs has been one of the key leaders of the SDDN since its origin. How did you get interested in the field of Drug Discovery? I come from a family of doctors — my father was a
- [A Closer Look at Ignacio Sancho-Martínez!](https://www.sddn.es/a-closer-look-at-ignacio-sancho-martinez/) - We’re excited to feature an interview with Ignacio Sancho-Martinez, who recently joined the SDDN Governing Board. Learn more about his background, his vision, and what drives his passion for science. How did you get interested in the field of Drug Discovery? Like many scientists, my curiosity started with an inspiring science teacher in high school,
- [Get to know Maria João Matos!](https://www.sddn.es/get-to-know-maria-joao-matos/) - We’re excited to feature an interview with Maria João Matos, who recently joined the SDDN Governing Board. Learn more about her background, her vision, and what drives her passion for science. How did you get interested in the field of Drug Discovery? When I was nine years old, I went with my mom to
- [New edition of BIOSPAIN confirmed: Heading to Bilbao in 2026](https://www.sddn.es/new-edition-of-biospain-confirmed-heading-to-bilbao-in-2026/) - The Spanish biotechnology ecosystem is already looking ahead to BIOSPAIN 2026, which will take place from September 29 to October 1, 2026, at the Bilbao Exhibition Centre. Organized by ASEBIO, BIOSPAIN has become one of the most important biotechnology events in Europe, bringing together researchers, companies, investors, and public institutions around innovation in healthcare, sustainable
- [Meet Rosario Fernández Godino!](https://www.sddn.es/meet-rosario-fernandez-godino/) - How did you get interested in the field of Drug Discovery? During my PhD and postdoc, I became an expert at creating cellular models of human diseases, with a special focus on cancer and retinopathies. The models helped to better understand the underlying mechanisms of pathology as well as to test drugs and biological therapies
- [Análisis y Propuesta de acciones para mejorar el impacto de la I+D preclínica en nuevas terapias en España](https://www.sddn.es/elementor-3831/) - Análisis y propuesta de acciones para mejorar el impacto de la I+D preclínica en nuevas terapias en España Documento PDF
- [SDDN2022 Satelite Workshop](https://www.sddn.es/sddn2022-satelite-workshop/) - SDDN2022 Satelite WorkshopInterested in new compound library initiatives? Register to the satellite workshop organized by Fundacion MEDINA on November 23 to present the EU-OPENSCREEN and ES-OpenScreen compound sourcing initiatives in Spain, side by side to the SDDN2022 conference.The workshop is directed to synthetic and natural products chemists interested in submitting their molecules to these new libraries
- [Ana Martinez Gil ha recibido el Premio Nacional de Investigacion Juan de la Cierva 2022 en el area de transferencia de tecnologia](https://www.sddn.es/ana-martinez-gil-ha-recibido-el-premio-nacional-de-investigacion-juan-de-la-cierva-2022-en-el-area-de-transferencia-de-tecnologia/) - Ana Martínez Gil ha recibido el Premio Nacional de Investigación Juan de la Cierva 2022, en el área de transferencia de tecnología. Ana Martínez Gil, vocal de la Junta Directiva de SDDN, ha sido reconocida por sus aportaciones en el campo del diseño y desarrollo de fármacos para enfermedades neurodegenerativas e infecciosas, destacando sus significativas
- [XIV SDDN Meeting Granada 2022](https://www.sddn.es/xiv-sddn-meeting-granada-2022-save-the-date/) - The XIV meeting of the Spanish Drug Discovery Network (SDDN) will take place in ParqueTecnológico de la Salud (PTS) / Universidad de Granada, in Granada, Spain, on November24 and 25, 2022. This international conference has become an ideal forum for the earlydrug discovery community, both from Academia and Industry. Every year we
- [ES-OPENSCREEN Satellite Workshop - October 7th, 2022- Santiago de Compostela](https://www.sddn.es/es-openscreen-satellite-workshop-december-7th-2022-santiago-de-compostela/) - Agenda ES-OPENSCREEN Satellite WorkshopPlease contact with Prof. Mabel Loza García if interested in attending: mabel.loza@usc.es ES-OPENSCREEN Satellite Workshop2nd EU-OPENSCREEN INDUSTRY LIAISON OFFICE Workshop Date: Friday 7th October 2022 Workshop location: Centro de Estudios Avanzados. Parque Vista Alegre, rúa Salvadas s/n, 15705. Santiago de Compostela, Spain14:30 – 15:00Introduction:– EU-OPENSCREEN ERIC. Wolfgang Fecke coordinator. (10 minutes).– European
- [SDDN Newsletter - Feb 2022](https://www.sddn.es/sddn-newsletter-feb-2022/) - As promised in the December Newsletter we will continue using this mechanism to keep you informed of the activities and developments of the Association. In this first 2022 Newsletter we want to highlight the relevance of populating the Observatory of Drug Discovery Capabilities and Capacities in Spain. The observatory, that

## Pages

- [Home](https://www.sddn.es/) - 21-23 de octubre de 2026 XVIII SDDN meeting PAMPLONA Connecting People, Sharing Knowledge, Discovering Therapies Más información SDDN es la Asociación de Profesionales del Descubrimiento y Desarrollo de Fármacos Asóciate a la SDDN “La Asociación de Profesionales del Descubrimiento y Desarrollo de Nuevas Terapias en España (SDDN) encuentra en su Congreso anual un evento científico
- [Programme2026](https://www.sddn.es/programme2026/) - ¡Ya puedes consultar el Programa del XVIII Congreso de la SDDN! Descarga el programa JORNADA SATÉLITE – MIÉRCOLES 21 DE OCTUBRE, 2025En el marco del Congreso Anual de la Spanish Drug Discovery Network (SDDN), que se celebrará los días 22 y 23 de octubre en la Universidad de Navarra, se organiza esta jornada previa con
- [XVIII SDDN Meeting 2026](https://www.sddn.es/xviii-sddn-meeting-2026/) - ¡Regístrate ya! ¡Se acerca la XVIII reunión de la SDDN! La XVIII reunión de la Red Española de Descubrimiento de Fármacos (SDDN) tendrá lugar en la Universidad de Navarra, en Pamplona, los días 22 y 23 de octubre de 2026. La tarde del día 21 de octubre se realizará una reunión satélite en Pamplona. Se
- [Lorena Boquete Vilariño](https://www.sddn.es/xviii-sddn-meeting-2026/ponentes/lorena-boquete-vilarino/) - Lorena Boquete Vilariño Galaria EPSS Brief CV:I am a Molecular Biologist with an MSc in Molecular Genetics and a PhD in Medical Studies. After my PhD, I worked at the Wellcome Sanger Institute as a Senior Research Assistant, specializing on the reprogramming of induced pluripotent stem cells and their differentiation into immune cells. Then I
- [Ángel Lucio](https://www.sddn.es/xviii-sddn-meeting-2026/ponentes/angel-lucio/) - Ángel Lucio Tetraneuron Brief CV:Ángel Lucio Pereira is the CEO of Tetraneuron, a Spanish biotechnology company specializing in gene therapies for neurodegenerative diseases. He has more than 18 years of international experience in the pharmaceutical and biotechnology industries, having held leadership positions at Johnson & Johnson, Takeda, Sanofi, and other multinational companies across business development,
- [Leire Escudero-Ibarz](https://www.sddn.es/xviii-sddn-meeting-2026/ponentes/leire-escudero-ibarz/) - Leire Escudero-Ibarz AstraZeneca Brief CV:Leire Escudero-Ibarz is an Associate Director at AstraZeneca, where she leads cross-functional teams in functional genomics and drug discovery across immunology, respiratory, oncology, and cell therapy. Her industry career spans GSK, Horizon Discovery, and AstraZeneca, building expertise in advanced perturbation screening platforms integrating multiomic readouts and AI-driven analysis to translate complex
- [Pablo Menéndez Buján](https://www.sddn.es/xviii-sddn-meeting-2026/ponentes/pablo-menendez-bujan/) - Pablo Menéndez Buján Instituto Josep Carreras - Sant Joan de Deu Hospital Brief CV:Born in Avilés, Asturias, in 1974 Dr Menendez studied Biochemistry at the University of Salamanca (1997) and received his PhD by the Department of Medicine (Hematology) from the same University in 2002, where he worked under the supervision of Prof Alberto Orfao
- [Marc Güell](https://www.sddn.es/xviii-sddn-meeting-2026/ponentes/marc-guell/) - Marc Güell Universitat Pompeu Fabra (UPF) Brief CV:ICREA Research Professor at Pompeu Fabra University. His work includes several synthetic biology breakthroughs (radically recoded genome, PERVs-free pigs, gene writing, skin microbiome engineering) that have produced important impact (>21,000 citations, 4 companies developing therapies, patents licensed to leading companies). He is an EMBO YI and member of
- [Anabel Perez](https://www.sddn.es/xviii-sddn-meeting-2026/ponentes/anabel-perez/) - Anabel Perez INBISTRA Brief CV:Anabel Pérez-Gómez, PhD, MBA, is COO and Managing Partner at INBISTRA, with more than 20 years of experience in preclinical development, R&D strategy and corporate partnerships. She advises companies and investors on operational strategy and portfolio decisions, and leads ARiDA, an AI platform for biotech analysis and decision support. Before co-founding
- [Ponentes](https://www.sddn.es/xviii-sddn-meeting-2026/ponentes/) - Ponentes Sesión 1: Drug Discovery Stories I Joana BrancoBiocant Science Park, PortugalSesión​: Título por definir. Rosario Fernández GodinoFundación MEDINASesión​: Redefiniendo el descubrimiento de fármacos contra el cáncer con IA e imagenología de alto contenido.
- [Sponsorship 2026](https://www.sddn.es/xviii-sddn-meeting-2026/sponsorship-2026/) - Expositores y patrocinadores SDDN ofrece la oportunidad de patrocinar y apoyar la reunión anual La reunión de la SDDN ofrece una excelente oportunidad para que las empresas den a conocer sus productos, servicios y tecnologías. El evento contará con un espacio de exposiciones especialmente diseñado para que puedan presentar sus innovaciones, así como con diversas
- [Exhibitors and Sponsors 2026 Description](https://www.sddn.es/exhibitors-and-sponsors-2026-description/) - Expositores y patrocinadores del XVIII SDDN MeetingLa SDDN ofrece la oportunidad de patrocinar y apoyar este evento clave del ecosistema del descubrimiento de fármacos, celebrado en Pamplona del 21 al 23 de Octubre. Ventajas de los socios y patrocinadores Nuestros Socios Almirall es una empresa global centrada en la salud de la piel, fundada en
- [Exhibitors and Sponsors](https://www.sddn.es/xviii-sddn-meeting-2026/exhibitors-and-sponsors/) - Expositores y patrocinadores SDDN ofrece la oportunidad de patrocinar y apoyar la reunión anual Ventajas de los socios y patrocinadores de eventos SDDN Socios ProtectoresEsta cifra va más allá de la participación en el evento concreto. Los Miembros de Apoyo tienen un papel muy importante en la sostenibilidad de la Asociación, y se espera de ellos
- [Socios protectores](https://www.sddn.es/socios-protectores/) - Socios Protectores [table id="10" responsive="" responsive_breakpoint=""] * Less than 5 years.Meeting sponsors’ fee does not include VAT. SDDN Partners fee is exempt from VAT. Socios Protectores de la SDDN
- [Página inscripción de pago](https://www.sddn.es/pagina-inscripcion-de-pago/) - Inscripciones y alojamiento Inscripción al Congreso ​ El idioma oficial de la reunión de la SDDN es el inglés.Puede registrarse online hasta el 18 de Octubre de 2026. Para más información sddn2026@sddn.es. Estudiantes Early hasta el 31 de julio100€ Standarddespués del 31 de julio125€ Dinner22/10/202660€ ( IVA incluido ) Regular - miembros SDDN Early hasta
- [Terms and conditions](https://www.sddn.es/terms-conditions/) - Cancellation and Refund TermsXVIII SDDN Meeting – Pamplona, 21-23 October 2026Spanish Drug Discovery NetworkCIF: B70325808 – Alba 3 Centro de Negocios, Edificio Fiteni IX, c/ Anabel Segura, 10, planta 3, 28108 Alcobendas (Madrid, Spain)Email: info@sddn.esThis document sets forth the cancellation, refund, and modification terms applicable to registration and participation in the XVIII SDDN Meeting (hereinafter, the
- [Join SDDN](https://www.sddn.es/join-sddn/) - Asóciate a SDDN Ser socio de la SDDN es formar parte de un grupo multidisciplinar de profesionales cuyo objetivo es contribuir activamente a la mejora del ecosistema español para el descubrimiento y desarrollo de nuevos fármacos.Cualquier persona que apoye los fines y objetivos de la Asociación puede ser miembro. Existen diferentes categorías de socios que
- [Eventos anteriores](https://www.sddn.es/eventos/) - Meetings anteriores > Ir a la Web del Congreso > Ir a la Web del Congreso > Ir a la Web del Congreso > Ir a la Posters Virtual Room 2023 > Ir a la Web del Congreso XIII Spanish Drug Discovery Network Meeting Madrid, 29 - 30 Noviembre, 2021 Ver la programación XII Spanish
- [XVII SDDN Meeting 2025](https://www.sddn.es/xvii-sddn-meeting-2025/) - Regístrate ya! ¡La XVII reunión de la SDDN ya está aquí!La XVII reunión de la Red Española de Descubrimiento de Fármacos (SDDN) tendrá lugar en el Hotel Attica de A Coruña los días 20 y 21 de noviembre de 2025. El día 19 de noviembre de 2025 se realizará una reunión satélite “Encuentro con el
- [Jornada MEGA 2025](https://www.sddn.es/jornada-mega-2025/) - Encuentro con el Sector biotecnológico de Galicia SDDN 2025 Jornada Satélite del XVII Congreso de la Sociedad Española de Descubrimiento de Fármacos (SDDN) 19 de noviembre de 2025 Museo Estrella Galicia, A Coruña Evento gratuito incluido con tu entrada al CongresoEn el marco del Congreso Anual de la Spanish Drug Discovery Network (SDDN), que se celebrará los días
- [Poster's virtual room 2025](https://www.sddn.es/posters-virtual-room-2025/) - Posters presented at the XVII SDDN Meeting - A Coruña 2025. Send us yours too ! ¿Cómo enviar tu póster? [table id="14" responsive="" responsive_breakpoint=""] Coorganizadores Socios Protectores de la SDDN Patrocinadores del XII Meeting de la SDDN
- [Exhibitors and Sponsors 2025 Description](https://www.sddn.es/exhibitors-and-sponsors-2025-description/) - Expositores y patrocinadores del XVII SDDN MeetingLa SDDN ofrece la oportunidad de patrocinar y apoyar este evento clave del ecosistema del descubrimiento de fármacos, celebrado en A Coruña del 19 al 21 de Noviembre. Ventajas de los socios y patrocinadores Nuestros Socios Almirall es una empresa global centrada en la salud de la piel, fundada
- [Posters - Information 2025](https://www.sddn.es/posters-information-2025/) - Información para los autores de pósters Los pósteres se exhibirán en formato físico en el Hall de Exposición. Para ello, el póster deberá presentarse impreso en persona durante la conferencia.Para ser aceptado, es requisito enviar al menos el resumen antes del 03 de noviembre.Los autores que lo deseen podrán enviar también el póster completo en
- [Programme2025](https://www.sddn.es/programme2025/) - ¡Ya puedes consultar el Programa del XVII Congreso de la SDDN! Descarga el programa JORNADA SATÉLITE – MIÉRCOLES 19 DE NOVIEMBRE, 2025En el marco del Congreso Anual de la Spanish Drug Discovery Network (SDDN), que se celebrará los días 20 y 21 de noviembre en el Hotel Ática 21, A Coruña, se organiza esta jornada
- [Página inscripción de pago](https://www.sddn.es/inscripciones-y-alojamiento/) - Inscripciones y alojamiento Inscripción al Congreso ​ El idioma oficial de la reunión de la SDDN es el inglés.Puede registrarse online hasta el 16 Noviembre. Para más información sddn@orzancongres.com Estudiantes Early hasta el 19 de septiembre100€ Standarddespués del 19 de septiembre125€ Dinner20/11/202560€ ( IVA incluido ) Regular - miembros SDDN Early hasta el 19 de septiembre200€
- [Ponentes](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/) - Descubre los ponentes del XVII SDDN Meeting, que se celebrará en A Coruña del 19 al 21 de Noviembre de 2025.
- [David Ochoa](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/david-ochoa/) - David Ochoa EMBL-EBI Short CV:David Ochoa joined Open Targets in 2019, where he currently works as the Platform and Informatics Science Coordinator. David is involved in setting the scientific strategy for informatics science projects and managing the day-to-day operations of core database projects in collaboration with industry partners. Before joining Open Targets, David obtained his
- [Jan Lichtenberg](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/jan-lichtenberg/) - Jan Lichtenberg InSphero Inc Short CV:Jan Lichtenberg, Ph.D., is Co-Founder and CEO InSphero Inc., the largest biotech specialized in 3D cell-culture technologies for discovery and safety. InSphero’s patented assay-ready 3D microtissues mimic the structure and functionality of organ tissue, e.g. liver, pancreas, or tumors including disease states like diabetes or MASH.He holds a Ph.D. from
- [Miriam Corredor](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/miriam-corredor-2/) - Miriam Corredor NoctuRNA Therapeutics Short CV:Miriam Corredor is CEO of NoctuRNA Therapeutics, a biotech company developing a circular RNA platform for neurodegenerative and other diseases. She holds a PhD in Medicinal Chemistry from Universitat Ramon Llull, with a thesis on drug discovery for neurodegeneration, and later completed a European postdoc resulting in several high-impact publications.
- [Javier Salgado Aguilera](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/javier-salgado-aguilera/) - Javier Salgado Aguilera BioLynx Short CV: Javier Salgado is co-founder of BioLynx, a community and career platform supporting young scientists across Spain. He holds a degree in Biotechnology and carried out a research stay at Harvard Medical School, working on liquid biopsy approaches for the early diagnosis of bladder cancer. Alongside his research experience, Javier
- [Roberto Rivilla Rodríguez](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/roberto-rivilla-rodriguez/) - Roberto Rivilla Rodríguez BioLynx Short CV:Roberto Rivilla is co-founder of BioLynx, a growing platform that connects young scientists with training, networking, and career opportunities across academia and industry. He holds a degree in Biotechnology and completed a research internship at the Medizinische Hochschule Hannover, where he investigated the role of specific metabolic changes in epithelial
- [Fernanda Ricci](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/fernanda-ricci-2/) - Fernanda Ricci Axxam SpA Short CV:Dr. Fernanda Ricci is Head of Advanced Cellular Assays at Axxam, an innovative CRO supporting the drug discovery journey. With over 15 years of experience in cell-based assays and phenotypic screening, she leads a multidisciplinary team specializing in high-content screening (HCS), iPSC-derived systems, and 3D cellular models. She holds a
- [Rosario Fernández Godino](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/rosario-fernandez-godino/) - Rosario Fernández Godino Fundación MEDINA Short CV: Abstract:La integración de la imagenología de alto contenido (HCI, por sus siglas en inglés) con modelos de cultivo en 3D (esferoides) que recrean la arquitectura tumoral in vivo ha revolucionado el campo del descubrimiento de fármacos contra el cáncer.MEDINA ha desarrollado una plataforma de cribado propia llamada m3DinAI
- [Ainara Vallejo](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/ainara-vallejo/) - Ainara Vallejo Miramoon Pharma (CSO) Brief CV:Soy Directora Científica (Chief Scientific Officer) y cofundadora de Miramoon Pharma SL, una empresa biotecnológica fundada en 2019 para desarrollar terapias innovadoras basadas en pequeñas moléculas dirigidas a enfermedades raras neuromusculares, cardíacas y neurodegenerativas.Con formación en Biología y un doctorada en Neurociencia, he construido mi carrera científica en torno
- [Estephan Arredondo](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/estephan-arredondo/) - Estephan Arredondo BeCytes Biotechnologies Brief CV:Estephan Arredondo, BS, MSc, es biólogo especializado en Donación de Órganos, Tejidos y Células por la Universidad de Barcelona. Actualmente es Director Técnico y Cofundador de BeCytes Biotechnologies, una empresa dedicada a la obtención de tejidos humanos y a la aislamiento de células primarias para el desarrollo de modelos avanzados
- [Marta Roccio](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/marta-roccio/) - Marta Roccio Universidad de Zurich Brief CV:Doctora en Biología Celular y Molecular por la Universidad de Utrecht (Países Bajos). Investigadora postdoctoral en el Centro Médico Universitario de Utrecht y en el Instituto Federal de Tecnología de Lausana (Suiza), donde trabajó en biología de células madre y bioingeniería. Jefa de grupo y profesora en el Laboratorio
- [Javier Terriente](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/javier-terriente/) - Javier Terriente T Drug Discovery, ZeCardio Brief CV: Abstract:
- [Alicia Higueruelo](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/alicia-higueruelo/) - Alicia Higueruelo Isomorphic Labs, London UK Brief CV: Abstract:Isomorphic Labs aspira a integrar la IA y la ciencia de la información para transformar el descubrimiento de fármacos, en la creencia de que la IA puede conducir a fármacos mejores y más asequibles para los pacientes. En esta charla se explicará cómo se emplean los modelos
- [Sonia Martínez Arca](https://www.sddn.es/xvii-sddn-meeting-2025/ponentes/sonia-martinez-arca/) - Sonia Martínez Arca Batea Oncology Brief CV:Investigadora y emprendedora en el sector de las Ciencias de la Vida, Farmacéutica y Doctora en Biología Molecular y Celular, desarrolló una carrera investigadora clásica durante más de diez años, hasta que en 2005 decidió dar el salto a la gestión con el objetivo de ayudar a transferir nuevas
- [Sponsorship 2025](https://www.sddn.es/xiv-sddn-meeting/sponsorship_2025/) - Expositores y patrocinadores SDDN ofrece la oportunidad de patrocinar y apoyar la reunión anual La reunión de la SDDN ofrece una excelente oportunidad para que las empresas den a conocer sus productos, servicios y tecnologías. El evento contará con un espacio de exposiciones especialmente diseñado para que puedan presentar sus innovaciones, así como con diversas
- [Registration cancellation policy](https://www.sddn.es/registration-cancellation-policy/) - Cancelation policy: Before 15 July – 100% refund of the registration fees paid From 15 July to 1 September – 50% refund of the registration fees paid From 1 September – are no longer eligible for a refund
- [Exhibitors and Sponsors 2024 Descripcion](https://www.sddn.es/xvi-sddn-meeting-2024-exhibitors-sponsors/) - Expositores y patrocinadores del XVI SDDN MeetingLa SDDN ofrece la oportunidad de patrocinar y apoyar este evento clave del ecosistema del descubrimiento de fármacos, celebrado en Valencia del 13 al 15 de Noviembre Ventajas de los socios y patrocinadores Nuestros Socios Almirall es una empresa global centrada en la salud de la piel, fundada en
- [Politica de Privacidad](https://www.sddn.es/politica-de-privacidad/) - Esta Web (web-SDDN) es titularidad de la Asociación Española de Profesionales del Descubrimiento y Desarrollo de Fármacos (SDDN), en adelante SDDN. La SDDN se constituyó el 1 de junio de 2021, estando inscrita en el Registro Nacional de Asociaciones, sección: 1a / número Nacional: 624692. El domicilio social de la Asociación una vez aprobada su
- [Gobernanza y Gestión](https://www.sddn.es/gobernanza-y-gestion/) - Gobernanza y GestionSDDN, Asociación Española de Profesionales del Descubrimiento y Desarrollo de Fármacos, se ha constituido como una organización de ámbito nacional sin ánimo de lucro al amparo de la Ley Orgánica 1/2002, de 22 de marzo, y normas complementarias, con personalidad jurídica y plena capacidad de obrar. En todo cuanto no esté previsto en
- [Actividades](https://www.sddn.es/actividades/) - Actividades Mentoring Mentoring program Capacity Map Capacity Map Webinars How and when to protect Drug Discoveries (DDs) through patents. Dialogue with Q&A between a researcher in DD and a patent attorney Fecha: Miércoles 27 de mayo, 16:00 -17:00 Ponentes: Manuel Illescas, socio director de MIAPatents, y José Manuel González, asociado en MIAPatents Sobre el webinar:
- [Poster's virtual room 2024](https://www.sddn.es/posters-virtual-room-2024/) - Pizarra de los tres finalistas del SLAS Tony B. Travel Award seleccionados para la sesión de flash talks (Viernes 15 , 13:00-13:30). Pósters presentados en el XVI SDDN Meeting - Valencia 2024¡Envíanos también el tuyo! ¿Cómo enviar tu póster? [table id="13" responsive="" responsive_breakpoint=""] Socios de la SDDN Patrocinadores de la SDDN
- [Programme2024](https://www.sddn.es/programme2024/) - DÍA 1 – MIÉRCOLES 13 DE NOVIEMBRE, 2024(SESIÓN CANCELADA)Esta sesión, prevista para mostrar las capacidades de la Comunidad Valenciana en terapias, diagnósticos y casos de éxito Biotech, ha sido cancelada y se reprogramará para enero de 2025 (fecha que se anunciará próximamente).DÍA 2 – JUEVES 14 DE NOVIEMBRE, 202409:00-10:00 Bienvenida y Sesión KeynoteModerador: Olga Genilloud (Fundación MEDINA)
- [Posters - Information 2024](https://www.sddn.es/posters-information-2024/) - Información para los autores de pósters Los pósters se expondrán en formato físico en la Sala de Exposiciones. Además, todos aquellos que deseen presentar un póster podrán registrar sus e-Pósters. Todos los inscritos tendrán acceso a los e-Posters a través de la Sala Virtual e-Poster que la organización habilitará en la web de la XVI Reunión
- [XVI SDDN Meeting 2024](https://www.sddn.es/xvi-sddn-meeting-2024/) - REGÍSTRATE ¡La XVI Conferencia de la SDDN ya está aquí !La XVI reunión de la Red Española de Descubrimiento de Fármacos (SDDN) tendrá lugar en la Fundación Valenciana de Investigación Biomédica (Centro de Investigación Príncipe Felipe, CIPF) del 13 al 15 de noviembre de 2024. Esta conferencia internacional se ha convertido en un foro de
- [Ximo Dopazo](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/ximo-dopazo/) - Joaquín Dopazo Plataforma de Medicina Computacional, Fundación Progreso y Salud, and Instituto de Biomedicina de Sevilla (IBIS) , Sevilla Brief CV: Dr. Joaquín Dopazo, the director of the Computational Medicine Platform of the Progress and Health Foundation of the Andalusian Health System, and Academic of the Spanish Royal Academy of Medicine (RANM), boasts a long
- [Speakers](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/) - Ponentes KeyNote Session 1 (SESSION CANCELLED) Ignacio Blanquer EspertI3M InstituteSesión​: European Cancer Imaging Initiative: Challenges and Opportunities.
- [Paula Río](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/paula-rio/) - Paula Río CIEMAT Brief CV: Paula Río, Biologist, PhD (UCM) is Head of the Bone Marrow Aplasia Unit at CIEMAT/CIBERER/IIS-FJD, UAM; Madrid. She has been working for more than 20 years in the field of gene therapy for Fanconi anemia, where she has focused on the design of a lentiviral vector for the correction of hematopoietic
- [Paula Fernández](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/paula-fernandez-2/) - Paula Fernández Laminar Pharma Brief CV: I obtained my PhD in Biochemistry from the University of Oviedo in 2012, I joined the same year the team of Dr. Pablo V. Escribá at the University of the Balearic Islands, firstly granted by the Marathon Foundation and after 1 year, I joined Laminar Pharma. During my first years
- [Ignacio Blanquer](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/ignacio_blanquer/) - Ignacio Blanquer I3M Institute Brief CV: Ignacio Blanquer is a member of the Computer System Department at UPV since 1999 (full professor since 2019). He is a researcher of the Grid and High-Performance Computing group of the Institute of Instrumentation for Molecular Imaging (I3M) since 1993 and became the leader of this group in 2015 and
- [Ángel Carracedo](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/angel-carracedo/) - Ángel Carracedo Universidad de Santiago de Compostela Brief CV: Prof Angel Carracedo (University of Santiago de Compostela) is Director of the Galician Foundation of Genomic Medicine (Galician Service of Health), Director of the Genomics and System Biology Group (CIMUS and IDIS), Director of Translational Medicine group and member board of CIBERER. President of Kaertor and INGADA
- [Luis Ruiz](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/luis-ruiz/) - Luis Ruiz Leukos Biotech Brief CV: Molecular Biologist PhD by training, with 10 years of classic academic research experience, joined the “dark side of the force” in 1998 as R&D project manager for the pharmaceutical industry. In 2001 became CEO of Advancell, the first biomedical spinoff from the University of Barcelona, and since then has
- [Beatriz LLamusí](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/beatriz-llamusi/) - Beatriz Llamusí Arthex Biotech Brief CV: Dr. Llamusí co-founded Arthex in December 2019 and was CEO of the company until May 2023 when the company raised its Series B. Since then Dr. Llamusi is CSO of Arthex Biotech. During the initial steps of the project that led to Arthex foundation, she was granted different competitive
- [Jordi Surrallés](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/jordi-surralles/) - Jordi Surrallés Inst. Reserca Hospital Sant Pau, Barcelona Brief CV: Prof. Surrallés is currently the Scientific Director of Sant Pau Hospital Biomedical Research Institute, with over >1200 researchers and 70 research teams. He is also Director of the Joint Research Unit in Genomic Medicine UAB-Sant Pau, and Coordinating Director of the Master of Medical Genetics
- [Miriam Andrés](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/miriam-andres/) - Miriam Andrés Almirall Brief CV: This is my background and professional journey in the field of Biological Sciences. I completed my Bachelor’s degree at the University of the Basque Country in 1994, followed by a PhD in Biochemistry and Molecular Biology. My research was conducted at the University of the Basque Country from 1995 to
- [Peter Simpson](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/peter-simpson/) - Peter Simpson Peter Simpson Consulting Brief CV:Professor Peter Simpson is a widely recognised strategic leader of UK life science companies, with a track record of driving innovation, growth, and impact. Through Peter Simpson Consulting Ltd he currently provides strategic advice and leadership support to a number of life science SMEs. He is Chair of Dia Beta
- [Philip Gribbon](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/philip-gribbon/) - Philip Gribbon EU-OPENSCREEN Brief CV: Philip is Director General of the of the EU-OPENSCREEN European Research Infrastructure for Chemical Biology and Screening in Berlin and Head of Discovery Research at the Fraunhofer Institute for Translational Medicine and Pharmacology in Hamburg, Germany and. He is involved in multiple national and European programs on both drug discovery
- [Mauro Muraro](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/mauro-muraro/) - Mauro Muraro Single Cell Discoveries Brief CV: Mauro is the CEO and Co-Founder of SCD. He studied systems biology at the University of Amsterdam and then spent one year at Mount Sinai in New York City to work on cellular reprogramming. At the conclusion of the program, he returned to the Netherlands to pursue his
- [Virginia Arechavala](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/virginia-arechavala/) - Virginia Arechavala Inst. Reserca Hospital Sant Pau, Barcelona Brief CV: Virginia Arechavala-Gomeza is an Ikerbasque Research Professor and leads the Nucleic Acids Therapies for Rare Diseases (NAT-RD) group at Biobizkaia HRI. With a background in pharmacy, she holds an MSc in Immunopharmacology and a PhD in the molecular basis of amyotrophic lateral sclerosis. During her
- [Geert Belgraver](https://www.sddn.es/xvi-sddn-meeting-2024/speakers/geert-belgraver/) - Geert Belgraver Pivot Park Screening Center Brief CV: Gerry is a biochemist with extensive pharmaceutical & molecular diagnostic experience {in high-throughput biomolecular and cellular screening} and currently serves as Director Business Development at Pivot Park Screening Centre (PPSC), a spin-off from the former Organon/MSD lead discovery screening unit in the Netherlands. At PPSC he is
- [XV SDDN Meeting 2023](https://www.sddn.es/xv-sddn-meeting-2023/) - ¡Guarda la fecha! LA XV reunión de la Spanish Drug Discovery Network (SDDN) tendrá lugar en el Parc de Recerca Biomèdica de Barcelona (PRBB) el 20 y 21 de noviembre de 2024. Esta conferencia internacional se ha convertido en un foro ideal para establecer contactos entre la comunidad dedicada al descubrimiento temprano de fármacos, tanto
- [slas-tony-b-award](https://www.sddn.es/slas-tony-b-award/)
- [Mentoring](https://www.sddn.es/mentoring/) - Mentoring We’re excited to announce the launch of the first edition of the SDDN Mentoring Program. This initiative aims to foster the exchange of knowledge between members of our scientific community, as we believe that our collective professional experience is an asset that the Association must leverage and make available to the youngest (or not so
- [Noticias](https://www.sddn.es/noticias/) - Noticias 29/06/2026 A Closer Look at Gijs Jochems We’re excited to feature an interview with Gijs Jochems, who recently retired as General Director of Promega, Spain. Gijs has been one of the key leaders of the SDDN since… Leer más 09/02/2026 A Closer Look at Ignacio Sancho-Martínez! We’re excited to feature an interview with Ignacio
- [Contacto](https://www.sddn.es/contacto/) - Contacto info@sddn.es+34 911 84 64 00Alba 3 Centro de NegociosEdificio Fiteni IXc/ Anabel Segura, 10, planta 328108 Alcobendas (Madrid) Mantente informado Nombre Email Mensaje He leído la política de protección de datos y autorizo a la SDDN a tratar mis datos para los fines descritos.* Sí, autorizo el envío de comunicaciones relacionadas con las actividades
- [Programme](https://www.sddn.es/xv-sddn-meeting-2023/programme/) - DÍA 1 – LUNES 20 DE NOVIEMBRE, 2023 09:00 – 09:30 Bienvenida y presentación del XV SDDN Meeting 09:30 – 12:00 Sesión 1: El impacto de herramientas basadas en IA y ciencia de datos en el descubrimiento de fármacos. Silla: Xavier Barril (Universidad de Barcelona). Ponentes Gianni De Fabritiis (Icrea/UPF and Acellera), Barcelona, Spain“Impacto de la
- [Speakers](https://www.sddn.es/xv-sddn-meeting-2023/speakers/) - Ponentes Sesión 1: El impacto de las herramientas basadas en IA y la ciencia de datos en el descubrimiento de fármacos. Silla: Xavier Barril (Universidad de Barcelona). Gianni De FabritiisIcrea/UPF y AcelleraSesión 1: El impacto de las herramientas basadas en IA y la ciencia de datos en el descubrimiento de fármacos.Charla: Impacto de la IA
- [Poster's virtual room](https://www.sddn.es/posters-virtual-room/) - Pizarra de los tres finalistas del SLAS Tony B. Travel Award seleccionados para la sesión de flash talks (Día 2, Martes 21 , 12:00-12:30). Pósters presentados en el XV SDDN Meeting - Barcelona 2023 [table id="5" responsive="" responsive_breakpoint=""] Socios de la SDDN Nuestros patrocinadores
- [Posters - Information for authors](https://www.sddn.es/xv-sddn-meeting-2023/posters-information-for-authors/) - Información para los presentadores de carteles Los pósters se expondrán en formato físico en la Sala de Exposiciones. Además, los presentadores de pósters podrán registrar sus e-Pósters. Todos los inscritos tendrán acceso a los e-Posters a través de la Sala Virtual e-Poster que la organización habilitará en la web de la XV Reunión SDDN. XV SDDN
- [Exhibitors and Sponsors](https://www.sddn.es/xv-sddn-meeting-2023/exhibitors-and-sponsors-2/) - Expositores y patrocinadores SDDN ofrece la oportunidad de patrocinar y apoyar este importante evento en la ciudad de Barcelona con diferentes opciones. Nuestros socios Almirall es una empresa global centrada en la salud de la piel, fundada en 1943 y con sede en Barcelona (España). Nuestro Noble Propósito es el núcleo de nuestro trabajo: “Transformar
- [XIV SDDN Meeting](https://www.sddn.es/xiv-sddn-meeting/) - > Registro La XIV reunión de la Spanish Drug Discovery Network (SDDN) tendrá lugar en el Parque Tecnológico de la Salud (PTS) / Universidad de Granada, en Granada, España, el 24 y 25 de Noviembre de 2022. Esta conferencia internacional se ha convertido en un foro de networking ideal para la comunidad del descubrimiento temprano
- [Sobre SDDN](https://www.sddn.es/sobre-sddn/) - Sobre SDDN Quiénes somos y a qué nos dedicamos SDDN es la Asociación de Profesionales del Descubrimiento y Desarrollo de Nuevas Terapias en España SDDN es la Asociación Española de Científicos y Profesionales dedicados al Descubrimiento y Desarrollo de Fármacos. Los miembros de la Asociación trabajamos tanto del mundo académico como de la Industria, y
- [Elementor #5812](https://www.sddn.es/elementor-5812/) - Email: info@sddn.es+34 911 84 64 00 Alba 3 Centro de NegociosEdificio Fiteni IXc/ Anabel Segura, 10, planta 328108 Alcobendas (Madrid)
- [Alfonso Rodríguez-Patón](https://www.sddn.es/xv-sddn-meeting-2023/speakers/alfonso-rodriguez-paton/) - Alfonso Rodriguez-Paton Predicting drug-target interactions with deep learning models Universidad Politécnica de Madrid (UPM) Alfonso Rodríguez-Patón is Catedrático (Full Professor) in Departamento de Inteligencia Artificial (Artificial Intelligence Department) of the Universidad Politécnica de Madrid (UPM). He got a Bachelor in Physics (1992), Master in Knowledge Engineering (1994), and a Ph.D. on DNA Computing (1999).Research in:
- [Juan Ruiz](https://www.sddn.es/xv-sddn-meeting-2023/speakers/juan-ruiz/) - Juan Ruiz Gene Therapy for Krabbe Disease Senior Vicepresident, Medical Affairs. Forge Biologics Krabbe disease (KD) is a devastating neurodegenerative disease caused by a lack offunctional galactosylceramidase (GALC) enzyme leading to cytotoxic build-up ofmetabolites such as psychosine. Myelin-producing cells are particularly sensitive tothese toxic metabolites, resulting in rapid loss of white matter in the central nervoussystem (CNS) and progressive demyelination in the peripheral nervoussystem (PNS). Infantile KD usually results in death
- [Mabel Loza](https://www.sddn.es/xv-sddn-meeting-2023/speakers/mabel-loza/) - Mabel Loza Creating value in Drug Discovery trough Public Private Partnerships Professor at university of Santiago de CompostelaThe process of Drug Discovery, which was traditionally restricted to the pharmaceutical companies, has in the latest decades evolved into a model where open innovation is now the norm rather than the exception. This allows the companies to
- [Gianni De Fabritiis​](https://www.sddn.es/xv-sddn-meeting-2023/speakers/gianni-de-fabritiis/) - Gianni De Fabritiis Impact of AI and physics-based drug discovery at Acellera Icrea/UPF and AcelleraCEO/CSO of Acellera and ICREA research professor at Universitat Pompeu Fabra where I lead the Computational Science Laboratory. I hold a bachelor degree with honors in applied mathematics (1997) from the Univ. of Bologna and a PhD from Univ. of London
- [Jose Carlos Segovia](https://www.sddn.es/xv-sddn-meeting-2023/speakers/jose-carlos-segovia/) - Jose Carlos Segovia Gene Therapy for Inherited Anemias: From Lentiviral to Gene Editing Strategies Cell Technology Division. Biomedical Innovation Unit. CIEMAT, MadridCV:Dr. Jose-Carlos Segovia is Doctor in Biological Sciences by the Universidad Autónoma de Madrid. Currently, he is Head of the Cell Technology Division and of the Flow Cytometry and Cell Separation Laboratory (LACISEP), at
- [Ramon Bosser](https://www.sddn.es/xv-sddn-meeting-2023/speakers/ramon-bosser/) - Ramon Bosser From Origo to Agomab, an ongoing success story Head of R&D Operations & Head of Spain, Agomab TherapeuticsAbstract: Origo started as a spin-off of Galchimia, targeting the TGF-beta pathway for the treatment of fibrosis. The differentiating factor was that this was done in an organ-restricted manner to prevent known systemic toxicities of other
- [Ricardo Gonzalo](https://www.sddn.es/xv-sddn-meeting-2023/speakers/ricardo-gonzalo-2/) - Ricardo Gonzalo Longitudinal omics data analysis of patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s Disease Plasma R&D, Scientific Innovation Office, Grifols, Barcelona, SpainAlzheimer’s disease (AD) is a neurodegenerative process cognitive decline. Key features of AD include the accumulation of plaques of amyloid-β peptide and the presence of neurofibrillary tangles.
- [Rafael Correa](https://www.sddn.es/xv-sddn-meeting-2023/speakers/rafael-correa/) - Rafael Correa Advanced cell therapy with Treg cells obtained from thymic tissue (thyTreg). A new paradigm in the treatment of inflammatory diseases “Laboratorio de Inmuno-Regulación. Instituto de Investigación Sanitaria Gregorio Marañón (IISGM)“ Abstract: “The adoptive transfer of regulatory T cells (Treg) has acquired a growing interest for controlling exacerbated inflammatory responses due to their suppressive
- [Robert Soliva](https://www.sddn.es/xv-sddn-meeting-2023/speakers/robert-soliva/) - Robert Soliva AI (r?)evolution. Have we learned from past waves of (r?)evolutionary technologies? AlmirallRobert Soliva took his BSc in Molecular Biology and Biochemistry at the University of Barcelona (UB), finishing his studies in the UK. Later, he took his PhD in computational chemistry in the group of Dr. Modesto Orozco (UB/ IRB-Institute of Research in
- [Maria Vinaixa](https://www.sddn.es/xv-sddn-meeting-2023/speakers/maria-vinaixa/) - Maria Vinaixa Advancing metabolomics technologies for drug discovery and development Universitat Rovira i Virgili (URV)1. Universitat Rovira i Virgili-Electronic Engineering Department-IISPV, Tarragona, Spain2. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), InsItuto de SaludCarlos III, Madrid, SpainAbstractWith the advance of analyIcal and computaIonal technologies, metabolomics exhibitsunprecedented possibiliIes for early drug development.1 Metabolomics can helpunderstanding disease
- [Jose Miguel Vela](https://www.sddn.es/xv-sddn-meeting-2023/speakers/jose-miguel-vela/) - Jose Miguel Vela From open innovation to joint public – private pharmaceutical R&D Welab BarcelonaJosé Miguel Vela obtained his Degree, Master’s Degree and PhD in the Autonomous University de Barcelona, where it was Associate professor engaged in teaching, mentoring and research for more than 10 years. Then, he moved to industry. He served on the
- [Javier Carmona](https://www.sddn.es/xv-sddn-meeting-2023/speakers/javier-carmona-2/) - Javier Carmona Precision oncology from a European perspective Hospital Vall d’HebrónEmployment History and Scientific BackgroundChief Scientific Officer – Cancer Core Europe (CCE) 2023–presentHead of Scientific Strategy – Vall d’Hebron Institute of Oncology (VHIO) 2022–presentVisiting Professor – Autonomous University of Barcelona 2023–presentMaster in Health & Science Management, Barcelona, Spain.Visiting Professor – University of Navarra 2021–presentMaster in
- [Antonio Pérez Martínez](https://www.sddn.es/xv-sddn-meeting-2023/speakers/antonio-perez-martinez/) - Antonio Pérez Martínez CAR-T cells engineering with NK cell properties Hospital La PazDr. Antonio Perez-Martinez (1974) holds a degree in Medicine and Surgery from the Faculty of Medicine of Granada (1998). He completed his Pediatrics residency at the Niño Jesús Children’s Hospital in Madrid (1999-2003), graduating a PhD from the Faculty of Medicine at UAM
- [Anji Miller](https://www.sddn.es/xv-sddn-meeting-2023/speakers/anji-miller/) - Anji Miller From Bench to Bedside: The Value of Promising Translational Research Skills lead, Innovation Hubs for Gene Therapies/ Senior Business Manager, LifeArc Anji is a TT professional with more than 19 years’ experience of working with early-stage translational research. Anji has extensive experience of IP and contract management, licensing, business development of healthcare technologies,
- [Alberto Santos Delgado](https://www.sddn.es/xv-sddn-meeting-2023/speakers/alberto-santos-delgado/) - Alberto Santos Delgado The Power of Graph Structures to Integrate, Analyze and Interpret Multi-omics Data DTU Biosustani Research CenterAlberto Santos is leading the Multi-omics Network Analytics research group (MoNA) and the Data Science Platform at the NNF Center for Biosustainability. Alberto’s research focuses on data science applied to multidisciplinary topics in biology and aiming to address complex challenges in planetary and human health. One
- [Albert Antolin](https://www.sddn.es/xv-sddn-meeting-2023/speakers/albert-antolin-2/) - Albert A. Antolin Harnessing AI in Drug Discovery & Development: Mind your Data Bellvitge Biomedical Research Institute (IDIBELL) and Catalan Institute of Oncology (ICO)Abstract: We are not maximally benefiting from the current explosion of information to discover more effective drugs. I will first present our efforts towards integrating and analysing Big Data to support cancer
- [Carla Minguet](https://www.sddn.es/xv-sddn-meeting-2023/speakers/carla-minguet/) - Carla Minguet - (DTU Biosustain Research Center), Copenhagen, DenmarkCarla Minguet-Parramona, PhD, Alzheimer’s Disease Scientist, Scientific Innovation Office, Grifols. PhD in Molecular Biology between the University of Glasgow and the University of Barcelona. MSc in Biostatistics and Bioinformatics at the Universitat Oberta de Catalunya.Since 2018 Carla has been part of the Grifols R&D team, focusing on
- [Julio Martín](https://www.sddn.es/xv-sddn-meeting-2023/speakers/julio-martin/) - Julio Martín Presentations SDDN Partners and Event Sponsors II SLAS European AmbassadorThroughout 29 years of experience in the R&D of a big pharma (GSK), I developed skills to combine Science and Business, two worlds apparently difficult to reconcile. The first looking for disruptive innovation, the second pursuing operational and business excellence. PhD in Biochemistry, Enzymologist
- [Dr. Barril](https://www.sddn.es/xv-sddn-meeting-2023/speakers/dr-barril/) - Xavier Barril Session 1: The impact of AI-based tools and data science in Drug Discovery ICREA & Universitat de BarcelonaDr. Barril is an ICREA Research Professor at the University of Barcelona, School of Pharmacy. His research focuses on the discovery of bioactive molecules exploiting new mechanisms of action and the development of computational methods to
- [Protección de datos](https://www.sddn.es/proteccion-de-datos/) - Protección de datos Responsable del tratamiento: La Asociacion Española de Profesionales del Descubrimiento y Desarrollo de Fármacos (SDDN), con domicilio social en Alba3-Centro de Negocios, C/Anabel Segura 10, 28108 Alcobendas, Madrid.Necesidad del tratamiento: La comunicación de sus datos es voluntaria.*Finalidad del tratamiento: Sus datos serán tratados para gestionar su registro como socio y para enviarle contenidos
- [Virtual classroom](https://www.sddn.es/virtual-classroom/) - Virtual classroom Automation-Enabled Target Engagement Selectivity Screening of Small Molecule Kinase Inhibitors Quantitative target engagement (TE) via bíoluminescence r,esonance energy transfer (BRET) methodologies enables non-permeabilized c live-cell high throughput profiling of drug candidates. To assess the precision Read More Development of novel luminescent assays for sensitive and specific quantitation of double-stranded RNA in mRNA vaccines
- [Poster's virtual room 2022](https://www.sddn.es/poster-presentados/) - Posters presented at the XIV SDDN Meeting - Granada 2022 [table id="4" responsive="" responsive_breakpoint=""]
- [Socios](https://www.sddn.es/socios/) - Socios Ser socio de la SDDN es formar parte de un grupo multidisciplinar de profesionales cuyo objetivo es contribuir activamente a la mejora del ecosistema español para el descubrimiento y desarrollo de nuevos fármacos. SDDN da la bienvenida a todos aquellos que participan en el difícil y costoso proceso del descubrimiento y desarrollo de nuevas
- [Venue](https://www.sddn.es/xv-sddn-meeting-2023/xv-sddn-meeting-2023-venue/) - SDDN Partners Our event sponsors
- [En construcción](https://www.sddn.es/en-construccion/) - Contents at some pages of the web site are under construction. Apologies for the invonvenience. To join SDDN o register at the XV SDDN Meeting to be held in Barcelona, 20-21 November 2023, click on the corresponding links at the home page or menu on top.
- [Registration](https://www.sddn.es/registration/)
- [](https://www.sddn.es/xiv-sddn-meeting/agenda/) - Programme Thursday, November 24th09:00 – 09:30 General Assembly – SDDN Association09:30 – 10:00 Welcome and Presentation of the XIV SDDN Meeting10:00 – 11:00 Session 1. Nucleic Acids as Therapeutic Agents11:00 – 11:30 Coffee Break11:30 – 12:30 Session 1. Nucleic Acids as Therapeutic Agents
- [Posters - Information for authors](https://www.sddn.es/xiv-sddn-meeting/posters/) - Information for poster presenters Posters will be displayed in physical format at the Exhibition Hall. In addition, poster presenters will be able to register their e-Posters. All registrants will have access to the e-Posters through the e-Poster Virtual Room that the organization will enable at the XIV SDDN meeting website. XIV SDDN Meting: SLAS Poster Award
- [Sponsor's and Exhibitor's presentations](https://www.sddn.es/sponsors-and-exhibitors-presentations/) - SDDN Sponsor's and Exhibitor's Presentations Thursday, November 24th 18:00 – 19:10 Friday, November 25th11:30 – 12:30 EMEAI Field Application Specialist 18:00Investigate Targeted Protein Degradation with AlphaLISA and HTRF technologies Head of Applications 11:30. CytoCHECK SPAchip® detection kits for dynamic real-time analysis of living single-cells CSO 18:20High-performance fluorescent probes to accelerate
- [Titles and Abstracts for Podium Presentations](https://www.sddn.es/titles-and-abstracts-for-podium-presentations/) - Session 1. Nucleic Acids as Therapeutic Agents Chair & Speaker: Tamara Martínez – Sylentis / Speakers: Mano Manoharan (Alnylam-USA), Miguel Moreno (Aptus Biotech – Spain) and Beatriz Llamusí (Arthex Biotech – Spain) Session 2 : How to potentiate Drug Discovery in Spain Chairs: Jorge Beleta (SDDN)/ Emilio Diez (e10Bio) / Speakers: Thomas Eichholtz, CSO (Chiesi
- [Virtual Room](https://www.sddn.es/xiv-sddn-meeting/virtual-room/) - This page will be available during the XIV SDDN Annual Meeting Organised by SDDN in collaboration with Fundacion MedinaFUNDACIÓN CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍAAVENIDA DEL CONOCIMIENTO 34, 18016 ARMILLACIF G18889444 Safety and Buyer Protection Cancellation of Orders, Return and refund Cookies Policy Safety and Buyer Protection Cancellation of Orders, Return
- [Venue and Accomodation](https://www.sddn.es/xiv-sddn-meeting/venue/) - Venue The XIV Spanish Drug Discovery Network Meeting will be held at the “Paraninfo de Servicios Centrales” of the University of Granada, at the PTS University Campus.”Address: PTS Auditorium. Av. de la Ilustración, 11P, 18016 Granada. The auditoria is located in the heart of the health technology park, the only science park in Spain specializing in
- [](https://www.sddn.es/xiv-sddn-meeting/registration/) - Registration XIV SDDN Meeting - Granada 2002 Attendance fees Before November 1st On November 1st or after Ordinary 125 € 150€ Students & Esarly Career Professionals & Retired 50 € 75 € By registering to the XIV SDDN meeting you will join as a member of SDDNFor those who are already members of SDDN ,
- [Session 2. How to potentiate Drug Discovery in Spain](https://www.sddn.es/xiv-sddn-meeting/podium-presentation-and-speakers-session-2/) - Session 2. How to potentiate Drug Discovery in Spain? The ability to generate novel therapies in Europe, and in particular in Spain, has been declining over the last few years. In parallel, there is a profound transformation in the models by which new drugs are discovered and developed.The session will address: 1) The current landscape
- [Socios Fundadores](https://www.sddn.es/socios-fundadores/)
- [Session 3. Targeted Protein Degradation](https://www.sddn.es/xiv-sddn-meeting/podium-presentation-and-speakers-session-3/) - Session 3. Targeted Protein Degradation In this session, we would like to focus on emerging technologies and approaches that will shape the future of TPD and expand the therapeutic impact of both glue degraders and bifunctional degraders (PROTACs). We would like to cover the following aspects:– Enriching the toolset of E3 ligases that can be
- [Session 5. Biologics in Drug Discovery and Development](https://www.sddn.es/xiv-sddn-meeting/podium-presentation-and-speakers-session-5/) - Session 5. Biologics in Drug Discovery and Development Currently, there is no doubt that biologic drugs stand for a real revolution in the global therapeutic market. According to the most recent data from the Antibody Society, there are 113 mAbs already approved by the FDA, 22 in review, and close to 600 in clinical trials.
- [Session 4. Antimicrobial Resistance and New Antibiotics](https://www.sddn.es/xiv-sddn-meeting/podium-presentation-and-speakers-session-4/) - Session 4. Antimicrobial Resistance and New Antibiotics The so-called “silent pandemic” is one of most relevant Global Health challenges facing humanity in the 21st century. It is a priority issue for the WHO, but it is also a prominent part of the agenda of the United Nations, the G20 or the G7. There is unanimous
- [Session 1. Nucleic Acids as Therapeutic Agents](https://www.sddn.es/xiv-sddn-meeting/podium-presentation-and-speakers/) - Session 1. Nucleic Acids as Therapeutic Agents The main objective of the Nucleic acid as Therapeutic Agents session is to give an overview of the setbacks and problems we have encountered in the RNA field and to show the hurdles we have faced and are facing to move forward with nucleic acid-based therapies. The cases
- [Jorge Beleta Supervia](https://www.sddn.es/socios-fundadores/jorge-beleta-supervia/) - Jorge received a B.Sc. in Biology in 1978 and a Ph.D. in 1986, both from Universitat Autònoma de Barcelona. After a post-doctoral stay during 1986-1987 at the Centre for Biotechnology, Imperial College London, working on protein engineering, he joined industry more than 35 years ago. The initial focus was on the development of new Clinical
- [](https://www.sddn.es/socios-fundadores/emilio-diez/) - Emilio Diez Monedero es Licenciado en Química y Dr. En Bioquímica por la Universidad Complutense de Madrid. Su carrera profesional ha transcurrido mayoritariamente en la Industria Farmacéutica y en el sector Biotecnológico con más de 30 años de experiencia liderando equipos de investigación internacionales multidisciplinarios en áreas que abarcan desde la identificación de dianas farmacológicas
- [Jose Julio Martín Plaza](https://www.sddn.es/socios-fundadores/jose-julio-martin-plaza/) - A lo largo de 29 años de experiencia en la I+D de una multinacional farmacéutica, he podido desarrollar habilidades para compaginar Ciencia y Gestión Empresarial, dos mundos aparentemente enfrentados y difíciles de conciliar. La primera en la búsqueda de la innovación disruptiva, la segunda persiguiendo la excelencia operacional y el negocio. La transformación de un
- [Maria Jesús Vicent Docón](https://www.sddn.es/socios-fundadores/maria-jesus-vicent-docon/) - Researcher unique identifier(s) (ORCID): A-9690-2014More information at http://www.VicentResearchLab.com La Dra María J. Vicent (nacida en Vila-real 1973) se doctoró en 2001 en química supramolecular y materiales en la Universidad Jaume I de Castellón después de varias estancias científicas en el laboratorio del Prof. Fréchet en la Universidad de California, Berkeley (USA). Posteriormente, su investigación se reorientó
- [Sessions](https://www.sddn.es/xiv-sddn-meeting/sessions/) - Scientific Sessions and Round Table Session 1. Nucleic Acids as Therapeutic Agents Chair & Speaker: Tamara Martínez - Sylentis / Speakers: Mano Manoharan (Alnylam-USA), Miguel Moreno (Aptus Biotech - Spain) and Beatriz Llamusí (Arthex Biotech - Spain) Session Goals The main objective of the Nucleic acid as Therapeutic Agents session is to give an overview
- [RGPD Congreso](https://www.sddn.es/rgpd-congreso/) - Política de Privacidad Congreso XIV de la Red Española de Descubrimiento de Fármacos (SDDN) tendrá lugar en el Parque Tecnológico de la Salud (PTS) / Universidad de Granada, en Granada, España, los días 24 y 25 de noviembre de 2022. La presente Política de Privacidad ha sido desarrollada teniendo en cuenta lo dispuesto por
- [Cookies Policy](https://www.sddn.es/cookies-policy/) - Cookies used on this website Following the guidelines of the Spanish Agency for Data Protection, we proceed to detail the use of cookies made by this website in order to inform you as accurately as possible. This website uses the following own cookies: Session cookies, to ensure that users who write comments on the blog
- [Politica de Cookies](https://www.sddn.es/politica-de-cookies/) - Cookies utilizadas en este sitio web Siguiendo las directrices de la Agencia Española de Protección de Datos procedemos a detallar el uso de cookies que hace este sitio web con el fin de informarle con la máxima exactitud posible. Este sitio web utiliza las siguientes cookies propias: Cookies de sesión, para garantizar que los
- [Aviso Legal](https://www.sddn.es/aviso-legal/) - Aviso legal Condiciones generales de acceso y uso del portal En cumplimiento con el deber de información dispuesto en la Ley 34/2002 de Servicios de la Sociedad de la Información y el Comercio Electrónico (LSSI-CE) de 11 de julio, se facilitan a continuación los siguientes datos de información general de nuestra web. Introducción y datos
- [Cancellation of Orders, Return and refund](https://www.sddn.es/cancellation-of-orders/) - Cancellations will be charged, and name changes must be made in writing and sent to the Technical Secretariat by email: secretariagranada2022@sddn.esUntil November 10th, the registration fee will be reimbursed, discounting 50% of the administrative charges. From November 10th, the cancellation of the registration will entail the loss of 100% of the payment. All refunds will
- [Safety and Buyer Protection](https://www.sddn.es/safety-and-buyer-protection/) - Payments for purchases at sddn.es are made through Redsys with all data transfer encryption and security systems through the SSL protocol, so that the buyer will enjoy at all times with the protection of these channels.
- [Tienda](https://www.sddn.es/tienda/)
- [Jordi Quintana Ruiz](https://www.sddn.es/socios-fundadores/jordi-quintana-ruiz/) - Jordi Quintana estudió química en el Instituto Químico de Sarriá (IQS) / Universitat Ramon Llull (URL), en Barcelona. Tras dos años en trabajando como químico de I+D en una empresa de polímeros, se trasladó a California, donde llevó a cabo su tesis doctoral en Bioquímica en la University of California, Los Angeles (UCLA), con una
- [Login](https://www.sddn.es/login/) - Username or Email Address Password Remember Me Log In Lost your password?

## Posters

- [Giving Synthesized Compounds a New Purpose: Public Spanish Chemical Library](https://www.sddn.es/poster/giving-synthesized-compounds/) - The Spanish Public Chemical Library (Quimioteca Publica Española, QPE) aims to maximize the value of compounds synthesized by Spanish academic groups by screening them against novel biological targets. This initiative offers these compounds a “second life” as chemical probes or potential drug candidates. QPE leverages three key strengths in Spain: the chemical diversity from academic
- [Automation-Enabled Target Engagement Selectivity Screening of Small Molecule Kinase Inhibitors](https://www.sddn.es/poster/automation-enabled-target-engagement-selectivity-screening-of-small-molecule-kinase-inhibitors/) - Quantitative target engagement (TE) via bíoluminescence r,esonance energy transfer (BRET) methodologies enables non-permeabilized c live-cell high throughput profiling of drug candidates. To assess the precision and repeatability of lhis technology, a selection of FDAapproved small molecules, and a set of published kinase inhibitors were screened in ciase-response titrations against a panel of 240 full length
- [Development of novel luminescent assays for sensitive and specific quantitation of double-stranded RNA in mRNA vaccines](https://www.sddn.es/poster/development-of-novel-luminescent/) - Abstract Poster
- [Advancing Predictive Preclinical Models with Beonchip Organ-on-Chip Technology](https://www.sddn.es/poster/advancing-predictive-preclinical-models-with-beonchip-organ-on-chip-technology/) - Sandra González-Lana, 1 Beatriz Sanz, 1 Lara Pancorbo, 1 Claudia Olaizola, 1 María Sainz, 1Inês Pereira, Luis Serrano, Rosa Monge 1 1 Beonchip S.L. Zaragoza, Spain. rmonge@beonchip.com Reproducing human physiology in vitro remains a major challenge in drug discovery, as the lack of predictive preclinical models often results in high attrition rates during clinical trials.
- [Development of a miniaturized phenotypic assay for drug screening in polycystic kidney disease](https://www.sddn.es/poster/phenotypic_assay/) - Polycystic kidney disease, particularly the autosomal dominant form (ADPKD), is a genetic disorder characterized by the formation of cysts derived from the renal tubular epithelium. Approximately 50 % of patients require dialysis or kidney replacement therapy before the age of 60 due to the limited efficacy and significant side effects of tolvaptan, the only approved
- [Identification of new targets for improving abiotic stress tolerance in plants](https://www.sddn.es/poster/identification-of-new-targets/) - Water availability is one of the main limitations for crop productivity. As droughts get more frequent and severe, it is important to improve plant’s drought tolerance. One strategy to reach this goal is the development of chemical compounds that are able to manipulate ABA signaling, thus promoting stomata closure and reducing water consumption. The main
- [Task-Specific Refinement of a Multitask AI Model for Blood–Brain Barrier Prediction](https://www.sddn.es/poster/task-specific-refinement/) - ADMET (absorption, distribution, metabolism, excretion and toxicity) issues remain one of the main reasons why otherwise promising small molecules fail late in the pipeline. Being able to screen these liabilities early, directly from structure, is therefore a practical way to de-risk discovery. In this work we take an existing ADMET-AI multitask graph neural network as
- [Photocaged chloroquine derivatives for the light-dependent inhibition of autophagy in cancer stem cells](https://www.sddn.es/poster/photocaged-chloroquine-derivatives-for-the-light-dependent-inhibition-of-autophagy-in-cancer-stem-cells/) - Achieving a localised effect of chemotherapy confined to the tumour site remains a major challenge in cancer treatment. Despite significant advances in targeted and precision medicine, many drugs still fail to discriminate between malignant and healthy cells, leading to narrow therapeutic windows and systemic toxicity. Therefore, novel therapeutic approaches that selectively direct drugs to the
- [EDDU: Early Drug Discovery Unit](https://www.sddn.es/poster/eddu-early-drug-discovery-unit/) - Early Drug Discovery Unit (EDDU) is specialized in the early stages of drug discovery, combining academic research with technology transfer to the chemical, pharmaceutical and biotechnology industries. We are a multidisciplinary team dedicated to developing new therapeutic solutions for a wide range of diseases. Our goal is to collaborate with companies, research centers, and universities,
- [Penicillin-based sulfone-siderophore conjugates for restoring beta-lactam antibiotic eddicacy in multidrug-resistant bacteria](https://www.sddn.es/poster/penicillin-based-sulfone/) - Membrane permeability serves as a natural defense barrier that contributes to increased drug resistance in bacteria, particularly among Gram-negative pathogens. Consequently, the accurate delivery of antibacterial agents to their intracellular targets has become a key area of research in infectious disease therapeutics, aiming to improve drug efficacy. Although efficient cytosolic transport of siderophore–antibiotic conjugates
- [Penicillin-based sulfone-siderophore conjugates for restoring beta-lactam antibiotic eddicacy in multidrug-resistant bacteria](https://www.sddn.es/poster/poster-penicillin/) - Membrane permeability serves as a natural defense barrier that contributes to increased drug resistance in bacteria, particularly among Gram-negative pathogens. Consequently, the accurate delivery of antibacterial agents to their intracellular targets has become a key area of research in infectious disease therapeutics, aiming to improve drug efficacy. Although efficient cytosolic transport of siderophore–antibiotic conjugates remain
- [Consensus-Enhaced Virtual Screening Unveils New Opportunities For Oncology Drug Desing](https://www.sddn.es/poster/consensus-enhaced-virtual/) - The discovery of selective and potent cancer inhibitors remains a major challenge due to the vastness of chemical space and the limitations of traditional virtual screening. Within the ULTRA project, we have developed and applied MetaScreener (https://github.com/bio-hpc/metascreener), a scalable, consensus-enhanced virtual screening framework that integrates structure-based, ligand-based, and AI-driven methodologies. This adaptive workflow allows the
- [Using Artificial Intelligence to Improve Drought Resistance in Crop Plants](https://www.sddn.es/poster/using-artificial-intelligence/) - Water is a necessary resource that sustains life on earth. Unfortunately, climate change is severely affecting rainfall, leading to a higher incidence of droughts that have a major impact on rain-fed farming systems, which account for 80 % of the world’s cropland and produce about 60 % of global agricultural output. Therefore, solutions to improve
- [Medicinal Chemistry and Plant Biology: Optimizing ABA-receptor Agonists for Drought Tolerance in Crops](https://www.sddn.es/poster/medicinal-chemistry-and-plant/) - Drought is the most destructive force in agriculture, causing annual losses of nearly 40 billion dollars worldwide. The FAO and UN have therefore emphasized the urgent need for innovative strategies to improve crop performance under water-limiting conditions. One effective approach is the activation of abscisic acid (ABA) signaling, which induces stomatal closure and broad physiological
- [Targeting Allosteric Sites in Drug Discovery](https://www.sddn.es/poster/targeting-allosteric-sites-in-drug-discovery/) - Targeting allosteric sites offers a highly selective and effective strategy for modulating protein function. Unlike traditional drugs that bind to active sites, allosteric modulators interact with distinct regulatory regions of a protein, enabling greater specificity and fewer side effects. These modulators fine-tune protein activity rather than completely inhibiting it, making them ideal for diseases that
- [Pioneering Plant PROTACs: Expanding the Agrochemical Toolbox](https://www.sddn.es/poster/pioneering-plant-protacs/) - Targeted Protein Degraders (TPDs) are small chemical molecules capable of inducing the degradation of specific target proteins1. Within this class, PROTACs (PROteolysis-Targeting Chimeras) have gained considerable interest in the pharma sector, although their potential in plant biology remains largely unexplored2,3. PROTACs are hetero-bifunctional molecules composed of a ligand that binds to the target protein, a
- [Preventing hypothermia through oral supplementation in mice](https://www.sddn.es/poster/preventing-hypothermia/) - Climate change is producing a dual effect: while global temperatures are rising on average, humans are becoming more vulnerable to cold due to reduced natural exposure and adaptation. At the same time, extreme cold events are becoming more frequent and intense. Each year, an estimated 4.5 million deaths are linked to cold exposure, accounting for
- [Reducing heat-stress mortality in poultry by oral supplements](https://www.sddn.es/poster/reducing-heat-stress/) - The global rise in temperatures is intensifying heat stress in farm animals, severely impacting their health, welfare, and productivity across the agricultural sector. In poultry, transport during even moderately warm days leads to significant mortality; between two and eight million chickens die annually in Spain alone, depending on the frequency of hot days, resulting in
- [Optimized 3D phenotypic assays for high-content and high-throughput screening in drug discovery](https://www.sddn.es/poster/optimized-3d-phenotypic/) - Three-dimensional (3D) in vitro models have emerged as powerful tools that bridge the gap between conventional two-dimensional (2D) cultures and in vivo systems. Traditional 2D cultures fail to replicate the natural cellular microenvironment due to limited cell–cell and cell–matrix interactions [1], whereas 3D models overcome these limitations, making them essential for tumor research, tissue engineering,
- [Development of a 3D pharmacological SH-SY5Y neurosphere model to study pathological mechanisms underlying cognitive impairment and its application in drug discovery](https://www.sddn.es/poster/development-of-a-3d/) - Cognitive impairment represents one of the most disabling symptoms of schizophrenia and remains poorly responsive to current pharmacological treatments. While two-dimensional (2D) neuronal models have provided valuable insights into cellular mechanisms, they are limited in capturing certain aspects of the spatial organization and intercellular communication relevant to neural network function. To complement these approaches, we
- [Unlocking Biological Insights Through AI-driven Multi-Omics Integration.](https://www.sddn.es/poster/unlocking-biological-insights-thro/) - Background: Multi-omics data integration is critical for understanding complex biological systems, but traditional approaches face scalability and interpretability challenges. Methods: We present two complementary frameworks: • MultiOmicsBind - A deep learning framework using ImageBind-inspired binding modality for efficient O(n) complexity multi-modal contrastive learning • OmicsNet - A network-based approach for visualizing and analyzing
- [Advancing Toxicity Prediction Through Autoencoder Analysis of High-Throughput Transcriptomics Data](https://www.sddn.es/poster/advancing-toxicity-prediction/) - Background : Predicting toxicological outcomes is crucial for human health and safety. Hight hroughput transcriptomics provides vast gene expression data requiring advanced analytical approaches for meaningful toxicity prediction. Methods: We leveraged autoencoders, unsupervised deep learning models, to analyze transcriptomics data. These encoder-decoder architectures compress gene expression profiles into latent representations, learning normal patterns and identifying
- [Differential activation of the JAK/STAT pathway in ulcerative colitis: analysis of the inflammatory response and sex-based variability](https://www.sddn.es/poster/differential-activation-of-the-jak-stat-pathway-in-ulcerative-colitis-analysis-of-the-inflammatory-response-and-sex-based-variability/) - Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by an excessive and dysregulated immune response in the intestinal mucosa. Among the intracellular signaling mechanisms implicated in this process, the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway plays a central role in mediating cytokine signaling and modulating inflammation. Despite the clinical use
- [Photopharmacology repurposing old GPCR targets with new smart drugs](https://www.sddn.es/poster/photopharmacology-repurposing-old/) - G protein-coupled receptors (GPCR) are the largest family of membrane receptors targeted by commercial drugs. However, the proportion of approved small molecules targeting GPCRs has slowed down within the last years. In large part. this is due to adverse effects or lack of efficacy found in clinical trials, which can be attributed to a low
- [Diverse approaches to 3D neural models: insights into organoid and spheroid systems for neurodegenerative disease research](https://www.sddn.es/poster/diverse-approaches/) - Three-dimensional (3D) neural culture systems, including organoids and spheroids, are increasingly recognized as powerful tools for modelling neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD). These models offer varying degrees of complexity, scalability, and physiological relevance. In this study we compare different approaches generating cerebral organoids and neural spheroids, highlighting their respective strengths
- [Study and Identification of G Protein-Coupled Receptor Interactions in an In Vitro Phenotypic Model of Schizophrenia: Effects of Antipsychotic Drugs](https://www.sddn.es/poster/study-and-identification/) - Schizophrenia is a chronic psychotic disorder with heterogeneous (positive, negative and cognitive) symptoms1. Although the etiopathogenesis has not been completely elucidated due to the complexity of the molecular mechanisms involved, dysregulation of the dopaminergic, glutamatergic and serotonergic neurotransmitter systems has been identified, involving ion channels of NMDA, several G protein-coupled receptors (GPCRs), such as D2,
- [Restoring Wnt signalling in the brain vasculature through inhibition of Notum enzyme: a Lead to Preclinical Candidate for Alzheimer’s disease.](https://www.sddn.es/poster/restoring-wnt/) - Motivation/problem statement: Alzheimer’s disease (AD) is a progressive neurodegenerative disease. No therapy has been found to alter its progression. Increasing evidence points to a deterioration of the blood brain barrier (BBB) and to the dysfunctionality of the neurovascular unit (NVU) as key components in AD. Wnt pathway regulates multiple cellular processes. Importantly, it maintains neurovascular
- [Reversing chemotherapy resistance in triple-negative breast cancer with natural compounds](https://www.sddn.es/poster/reversing-chemotherapy/) - Triple-negative breast cancer (TNBC) is the most aggressive and heterogeneous subtype of breast cancer, which lack therapeutic targets like estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Therefore, chemotherapy with antiproliferative agents like Docetaxel (DTX) remains the standard of care for TNBC patients. Unfortunately, many tumors acquire resistance to
- [4-aryl-1,2-dithiole-3-thiones: synthesis, antimicrobial activity, and molecular docking insights](https://www.sddn.es/poster/4-aryl-12-dithiole/) - 4-Aryl-1,2-dithiole-3-thione derivatives are sulfur-containing heterocycles recognized for their broad-spectrum biological activities. In this study, two derivatives were synthesized via Field’s method (1955),1 and structurally characterized using FT-IR, 1H NMR, 13C NMR, and mass spectrometry. Their antimicrobial activity was assessed against selected bacterial and fungal strains using the disc diffusion method, as well as MIC and
- [Microfluidic chip for advanced blood-brain barrier co-culture](https://www.sddn.es/poster/microfluidic-chip/) - We present a microfluidic platform developed by Bflow designed to create a in vitro Blood-Brain Barrier (BBB) model for drug screening and neuroscience research. The chip, fabricated in biocompatible PDMS using a scalable process based on 3D micro-printed resin templates, incorporates a three-channel architecture: a wide channel for culturing endothelial cells under physiological shear stress,
- [Novel Benzothiazole derivates for the treatment of neurodegenerative disorders: study in phenotypic alzheimer's disease model](https://www.sddn.es/poster/novel-benzothiazole/) - Alzheimer’s disease is the most common cause of dementia, and its associated cost represents a staggering weight for world economies. Its current treatment is merely symptomatic, thus making the search for new drugs capable of altering the course of the disease of great interest. Drugs currently in therapeutics for other neurodegenerative diseases such as riluzole
- [Protease-Activated Trojan Horses: A New Route to Defeat Acinetobacter baumannii](https://www.sddn.es/poster/protease-activated-trojan/) - Multidrug-resistant (MDR) Acinetobacter baumannii is a major global health concern, responsible for severe hospital-acquired infections such as pneumonia, septicemia, and sepsis. Its ability to persist under adverse conditions and acquire antibiotic resistance mechanisms has led the World Health Organization to classify it as a critical priority pathogen, highlighting the urgent need for new antibacterial approaches
- [INTEGRATION OF LIVER TUMOR ORGANOIDS AND IN SILICO METHODS TO ADDRESS DRUG RESISTANCE (LIVERtera)](https://www.sddn.es/poster/integration-of-liver-tumor-organoids-and-in-silico-methods-to-address-drug-resistance-livertera/) - Introduction Organoid technology has recently revolutionized research in hepatic oncology. Approaching drug resistance is essential to meet current clinical needs, particularly in hepatocellular carcinoma (HCC) and liver-metastatic colorectal cancer (mCRC). Standard-of-care (SoC) treatments are sorafenib for HCC and cetuximab for mCRC and have shown potent antitumor activity. However, resistance frequently develops, leaving patients with limited
- [A novel pro-apoptotic-based combination therapy for pediatric solid tumor treatment](https://www.sddn.es/poster/a-novel-pro-apoptotic/) - Despite advances in pediatric oncology, solid tumors, which account for ~30% of childhood cancers, remain a leading cause of mortality due largely to late diagnosis, therapeutic resistance, and a lack of effective treatment options [1,2]. Current disease management remains suboptimal, underscoring the need for innovative therapeutic strategies to overcome these challenges. One promising approach involves
- [Validation of an antitumor compound in 2D and 3D gliobastoma models](https://www.sddn.es/poster/validation-of-an-antitumor-compound-in-2d-and-3d-gliobastoma-models/) - The RB-E2F pathway has a critical role in the control of cell proliferation and, therefore, a valuable therapeutic strategy in cancer could be the decreasing of E2F hyperactivity. Furthermore, the disruption of the PARP1-E2F1 interaction could provide a new therapeutic target for various tumor types, considering that most oncogenic processes are associated with cell cycle
- [Structural Insights on adenosine A2A / A2B dual antagonism by free energy perturbation](https://www.sddn.es/poster/structural_insights/) - Cancer is one of the leading causes of death across the world, which needs proper diagnosis and effective treatment. Over the last decade, immune-oncology therapies have achieved breakthrough records of survival rates for several types of cancer. However, multiple metabolic dysregulations in the tumor microenvironment promote immunosuppression. One of such is the high concentration of
- [Testeo](https://www.sddn.es/poster/testeo/)
- [Liposomal Formulations of Gold(III) Complexes against Multidrug Resistant Staphyloccocus spp. strains](https://www.sddn.es/poster/liposomal-formulations-of-goldiii-complexes-against-multidrug-resistant-staphyloccocus-spp-strains/) - Marina Cano,1 Enmanuel Cornielle,2 Alejandro Llamedo,1 Paula Pérez-Ramos,3 Pelayo A. Buelga,3 Humberto Rodríguez-Solla,3 Sara M. Soto,2,4 and Raquel G. Soengas3 1 Nalón Innova, Avenida de Galicia 31, 33005, Oviedo, Spain 2 ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain 3 Departamento de Química Orgánica e Inorgánica, Instituto Universitario de Química Organometálica“Enrique Moles”, Universidad de
- [Alba Synchrotron: A Cutting-Edge Resource for Pharmaceutical Companies](https://www.sddn.es/poster/alba-synchrotron-a-cutting-edge-resource-for-pharmaceutical-companies-2/) - Núria Valls1 1ALBA Synchrotron nvalls@cells.es ALBA Synchrotron is a state-of-the-art facility comprising a complex of electron accelerators that produce synchrotron light, enabling high-resolution visualization of the atomic structure of matter and in-depth analysis of its properties. ALBA offers a diverse array of applications, particularly within the pharmaceutical sector. The different instruments available at ALBA
- [Use of the SEE-Tx Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type](https://www.sddn.es/poster/use-of-the-see-tx-drug-discovery-platform-to-identify-pharmacological-chaperones-for-glutaric-acidemia-type/) - Elena Cubero, Madalena Barroso, Alexandra Puchwein-Schwepcke, Lars Buettner, Ingrid Goebel, Katrin Küchler, Ania C. Muntau, Aida Delgado, Ana María García-Collazo, Marc Martinell, Xavier Barril1 and Søren W. Gersting. Gain Therapeutics Sucursal en España, Barcelona, Spain; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Ludwig-Maximilians-University, Munich, Germany; Minoryx Therapeutics S.L., Mataró, Barcelona, Spain. Allosteric regulators acting as pharmacological chaperones have
- [Comprehensive in vivo multiomics analysis of Alzheimer ' s disease pathogenesis in plasma](https://www.sddn.es/poster/comprehensive-in-vivo-multiomics-analysis-of-alzheimer-s-disease-pathogenesis-in-plasma/) - S. Yeste, S.Benabou, S.Mehta and P.Bonini OloBion SL, Barcelona, Spain. Alzheimer’s disease (AD), affecting over 24 million people worldwide, remains the leading cause of dementia, underscoring the critical need for new therapeutic targets. Conventional research has predominantly focused on the amyloid cascade hypothesis, which attributes AD pathogenesis to the aggregation of amyloid-β protein. Yet, this
- [QSAR modelling for the prediction of pharmacokinetic and bioactivity properties of peptide-based drugs](https://www.sddn.es/poster/qsar-modelling-for-the-prediction-of-pharmacokinetic-and-bioactivity-properties-of-peptide-based-drugs/) - Carmen Ortiz-González, Laureano E. Carpio, Eva Serrano-Candelas, Rafael Gozalbes. ProtoQSAR SL, c/ Nicolás Copérnico 6, Parque Tecnológico de Valencia, Paterna, Spain. MolDrug AI Systems SL, Parque Tecnológico de Valencia, Paterna, Spain. Peptides are molecules composed of 2 to 50 amino acids that can be used as drugs or drug candidates, as an alternative to small
- [Use of Polypeptide-Based Nanoconjugates as a Combination Therapy Approach to treat Retinitis Pigmentosa](https://www.sddn.es/poster/use-of-polypeptide-based-nanoconjugates-as-a-combination-therapy-approach-to-treat-retinitis-pigmentosa/) - S. Velasco, I. Conejos-Sánchez2, E. Masía, L. Olivares-González, Regina Rodrigo and M.J. Vicent Pathophysiology and Therapy for Vision Disorders Lab., CIPF (Centro de Investigación Príncipe Felipe), Valencia, Spain (svelasco@cipf.es) Polymer Therapeutics Lab., CIPF (Centro de Investigación Príncipe Felipe), and CIBERONC, Valencia, Spain. Inherited retinal dystrophies (IRDs) are a group of diseases which affect the retina
- [Lab-in-a-cell SPAchip® sensing and filming live-cell physiology of relevance for drug discovery](https://www.sddn.es/poster/lab-in-a-cell-spachip-sensing-and-filming-live-cell-physiology-of-relevance-for-drug-discovery/) - Jose Julio Martín. Senior Strategic Liaison, Arrays for Cell Nanodevices, S.L. Live-cell imaging in drug discovery and cell biology research is hampered by drawbacks of traditional fluorescent chemical probes in solution, such as cytotoxicity over time, difficulty of multiplexing, expelling of molecular from cell, and poor cell penetration. Continuous monitoring of specific hallmarks for signalling,
- [m3DinAI Drug Quest: A Machine Learning-Driven Platform for HighThroughput Screening of antitumoral agents in 3D Cancer Models](https://www.sddn.es/poster/m3dinai-drug-quest-a-machine-learning-driven-platform-for-highthroughput-screening-of-antitumoral-agents-in-3d-cancer-models/) - Inmaculada Iáñez, Marta Martínez-García, María C. Ramos-Martín, Rosario Fernández Godino. Fundación MEDINA (MEDI), Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento 34, 18016 Granada, Spain. The use of 3D spheroids that mimic tumor microenvironment has advanced significantly the cancer drug discovery field. However, characterizing and quantifying phenotypic alterations in spheroids treated with drugs
- [Exploring Antipsychotic-Induced Changes in Peripheral Sensory Neurons: Insights from the F11 Cell Line](https://www.sddn.es/poster/exploring-antipsychotic-induced-changes-in-peripheral-sensory-neurons-insights-from-the-f11-cell-line/) - López, D., Orduna J., Brea J., Martínez A.L., Loza, M.I University of Santiago de Compostela, Santiago de Compostela, Spain Antipsychotics have known effects on the development of neurons and in neurite length in the central nervous system (Frost et al., 2010). However, their effects on peripheral neurons are not well understood, and data on their
- [Study of Dopamine and Glutamate Receptor Oligomerization on the Effect of Antipsychotic Drugs in an In Vitro Phenotypic Model of Schizophrenia](https://www.sddn.es/poster/study-of-dopamine-and-glutamate-receptor-oligomerization-on-the-effect-of-antipsychotic-drugs-in-an-in-vitro-phenotypic-model-of-schizophrenia/) - Leslye Paola Valarezo Riascos, José Manuel Brea Floriani. Biopharma Group, Singular Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela. 15782 - Santiago de Compostela (Spain). Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela. 15782 - Santiago de Compostela (Spain). Schizophrenia is a chronic psychotic illness
- [Bi-functional nanoparticles as new immunotherapeutic approach to re-establish communication between cancer and immune cells](https://www.sddn.es/poster/bi-functional-nanoparticles-as-new-immunotherapeutic-approach-to-re-establish-communication-between-cancer-and-immune-cells/) - Sandra Clara-Trujillo, Alba Ortuño-Bernal, Elena Lucena-Sánchez, Francisco J.Hicke, Andrea Escudero, Sandra Pradana-López, Paula Díez, Alba García-Fernández, Ramón Martínez Máñez. Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM) Universitat de València–Universitat Politècnica de València, Camino de Vera s/n, 46022, Valencia, Spain. CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III. Unidad
- [Comparative profiling of whole-cell and exosome samples reveals protein signatures that stratify breast cancer subtypes](https://www.sddn.es/poster/comparative-profiling-of-whole-cell-and-exosome-samples-reveals-protein-signatures-that-stratify-breast-cancer-subtypes/) - Zoraida Andreu, Marta R. Hidalgo, Esther Masiá, Sergio Romera-Giner, Pablo Malmierca-Merlo, José A. López-Guerrero, Francisco García-García, María J. Vicent The identification of novel breast cancer biomarkers will improve patient stratification, enhance therapeutic outcomes, and help to develop non-invasive diagnostics. Herein, we present the proteomic and functional characterization of breast cancer cells (BCCs) and breast cancer
- [Making better antibodies, faster and cheaper thanks to AI](https://www.sddn.es/poster/making-better-antibodies-faster-and-cheaper-thanks-to-ai/) - Guillermo Llopis, Founder and CEO, ProtForge At ProtForge we can develop better antibodies for any kind of application. We have a generative model that can be adapted to include specific metrics and data, so instead of just doing a traditional optimization, it can design the proper antibody. Our results show outstanding success rates for de
- [Enhancing drug assessment for Duchenne muscular dystrophy using organ-on-a-chip technology and nanoplasmonic biosensing of myotube integrity](https://www.sddn.es/poster/enhancing-drug-assessment-for-duchenne-muscular-dystrophy-using-organ-on-a-chip-technology-and-nanoplasmonic-biosensing-of-myotube-integrity/) - Ainoa Tejedera-Villafranca, María J Ugarte-Orozco, Martín Ruiz-Gutiérrez, Armando Cortés‐Reséndiz, Javier Ramón-Azcón and Juan M. Fernández-Costa. Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain Duchenne muscular dystrophy (DMD) poses significant challenges for drug development, given its complex and
- [3D bioengineered liver for the study of acute and chronic hepatic damage](https://www.sddn.es/poster/3d-bioengineered-liver-for-the-study-of-acute-and-chronic-hepatic-damage/) - Ainhoa Ferret-Miñana, Estefanía Alcaraz, Raquel Horrillo, Javier Ramón-Azcón, and Francesco De Chiara. Biosensors for Bioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain. Scientific Innovation Office, Grifols, Barcelona, Spain. ICREA-Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. The liver, a vital organ, faces acute and chronic insults that disrupt its normal function. Acute
- [Zinc phthalocyanine-initiated poly-L-glutamate-based nanocarriers with theranostic properties for glioblastoma multiforme treatment](https://www.sddn.es/poster/zinc-phthalocyanine-initiated-poly-l-glutamate-based-nanocarriers-with-theranostic-properties-for-glioblastoma-multiforme-treatment/) - Amina Benaicha-Fernández (CIPF, Spain), María Medel, Esther Masià, Inmaculada Conejos-Sánchez, and María J. Vicent (CIPF/CIBERONC, Polymer Therapeutics Lab, Valencia, Spain). Introduction: Glioblastoma multiforme (GBM) - the most common class of malignant primary brain tumors in adults- is known for its aggressiveness and poor survival rates[1]. To overcome inefficiencies associated with current GBM therapies, as most
- [Development of new drug delivery systems based on polymeric  nanofibers for glioblastoma treatment](https://www.sddn.es/poster/development-of-new-drug-delivery-systems-based-on-polymeric-nanofibers-for-glioblastoma-treatment/) - Pedro V. Badía-Hernández, Joan Moll-Carrió1, María Fuentes-Baile, Amalia Mira Carrió, Rocío Díaz-Puertas, Ma Pilar García-Morales, Ricardo Mallavia. Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE-UMH), Universidad Miguel Hernández de Elche, Alicante, España. Glioblastoma is a type of glioma with a low incidence but a high mortality rate due to its malignancy.
- [Automated Workflow for Error-Reduction, Time Efficiency, and Labor Minimization in Sample Management Using Echo 650 and Robotic Integration](https://www.sddn.es/poster/automated-workflow-for-error-reduction-time-efficiency-and-labor-minimization-in-sample-management-using-echo-650-and-robotic-integration/) - Alejandro Rodríguez-Pena, Jose Manuel Ramos, María Isabel Iglesias, Geert A. Daudey, Antón Leandro Martínez, Jose Manuel Brea Floriani, María Isabel Loza García. Innopharma Drug Screening and Pharmacogenomics Platform. Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain In high-throughput screening and sample management, ensuring accuracy,
- [Characterization of JAK/STAT Pathway Activation in Ulcerative Colitis: A Methodology for Identifying Activation Patterns Towards Personalized Treatment Approaches.](https://www.sddn.es/poster/characterization-of-jak-stat-pathway-activation-in-ulcerative-colitis-a-methodology-for-identifying-activation-patterns-towards-personalized-treatment-approaches/) - Mariña Durán-Rubí, David Moreira-Alvarez, Iria Brocos-Mosquera, Cristina Calviño, Manuel Barreiro, María Isabel Loza, Antón Martínez. Singular Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Santiago de Compostela, Spain. University Hospital Complex of Santiago de Compostela (CHUS), Santiago de Compostela, Spain. Ulcerative colitis (UC) is a disease characterized by continuous inflammation and colon ulcer
- [Computational exploration of PPARα agonists: integrating ligand- and structure-based modeling for targeted drug discovery](https://www.sddn.es/poster/computational-exploration-of-pparα-agonists-integrating-ligand-and-structure-based-modeling-for-targeted-drug-discovery/) - Laureano E. Carpio, Rita Ortega-Vallbona, David Talavera-Cortés, Addel Goya-Jorge, Eva Serrano-Candelas, Rafael Gozalbes. MolDrug AI Systems SL, Valencia, Spain. ProtoQSAR SL, CEEI Parque Tecnológico de Valencia, Spain. Type 2 diabetes mellitus (T2DM) is a major public health issue, characterized by hyperglycemia due to insulin resistance and/or insufficient insulin production. Uncontrolled T2DM can lead to severe
- [ALBA Synchrotron: A Cutting-Edge Resource for Pharmaceutical Companies](https://www.sddn.es/poster/alba-synchrotron-a-cutting-edge-resource-for-pharmaceutical-companies/) - Núria Valls, ALBA Synchrotron, nvalls@cells.es ALBA Synchrotron is a state-of-the-art facility comprising a complex of electron accelerators that produce synchrotron light, enabling high-resolution visualization of the atomic structure of matter and in-depth analysis of its properties. ALBA offers a diverse array of applications, particularly within the pharmaceutical sector. The different instruments available at ALBA are
- [UNLOOC PROJECT: Unlocking the data content of Organ-on-Chips](https://www.sddn.es/poster/unlooc-project-unlocking-the-data-content-of-organ-on-chips/) - Rosa Monge, Beatriz Sanz, Sandra González, Lara Pancorbo, María Sainz, Claudia Olaizola, Inês Pereira, Luis E. Serrano. Beonchip S.L., Zaragoza, Spain. UNLOOC is a 3-year project tackling the challenge inherent in animal testing of drugs. It brings together 51 organisations from 10 European countries. The consortium aims to demonstrate through its five novel use cases
- [Seeing is Believing: Enabling Functional Imaging of NanoLuc® Technologies with Bioluminescence Microscopy](https://www.sddn.es/poster/seeing-is-believing-enabling-functional-imaging-of-nanoluc-technologies-with-bioluminescence-microscopy/) - Kristin Riching, Joseph Bessetti, Brandilyn Bennett, Michael Bjerke, María Jurado Pueyo, Gijs Jochems. Promega Corporation, 2800 Woods Hollow Rd, Madison, WI, 53711 Promega Biotech Ibérica, Av Bruselas 5, Alcobendas, Madrid 28108, Spain Research for new therapeutics often use cell-based assays with microplate readers to generate relative light unit (RLU) and relative fluorescence unit (RFU) values
- [High performance TR-FRET assays for the measurement of phosphorylated human STAT1, STAT3 and STAT6 in cell lysates using THUNDER TR-FRET](https://www.sddn.es/poster/high-performance-tr-fret-assays-for-the-measurement-of-phosphorylated-human-stat1-stat3-and-stat6-in-cell-lysates-using-thunder-tr-fret/) - Name of Authors: Geneviève Chatel, Mireille Caron and Jaime Padros Name of Institution: BioAuxilium The Signal Transducer and Activator of Transcription (STAT) family of proteins plays a complex and essential role in mediating cellular responses to cytokines and growth factors. The abnormal activation of STAT proteins, including STAT1, STAT3 and STAT6, has been associated with
- [Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes, applied to EU-OPENSCREEN compound library](https://www.sddn.es/poster/cell-painting-a-high-content-image-based-assay-for-morphological-profiling-using-multiplexed-fluorescent-dyes-applied-to-eu-openscreen-compound-library/) - Carmen Ramos, C. Wolff, M. Neuenschwander, J. Brea, M. Varela, P. Dzubak, A. Srovnalova, I. Iáñez, P. Gibbon, O. Genilloud, R. Fernandez-Godino, C. Schmied Fundación MEDINA Fundacion MEDINA (MEDI) is one of the partner sides of EU-OPENSCREEN (EU-OS), which is a not-forprofit European Research Infrastructure Consortium (ERIC) for chemical biology and early drug discovery. EU-OS
- [High Throughput Kinase Inhibitor Profiling in Live Cells with NanoBRETTM Target Engagement K192 Kinase Selectivity System](https://www.sddn.es/poster/high-throughput-kinase-inhibitor-profiling-in-live-cells-with-nanobrettm-target-engagement-k192-kinase-selectivity-system/) - Name of Authors: Iván Marcos Name of Institution: Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711 e-mail: ivan.marcos@promega.com Poster Congreso SDDN 2023
- [EU-OPENSCREEN / ES-OPENSCREEN Academic Compound Library Initiative](https://www.sddn.es/poster/eu-openscreen-es-openscreen-academic-compound-library-initiative/) - Name of Authors: Geert A. Daudey, Mabel Loza Garcia, Bahne Stechmann, and Victoria Mora Name of Institution: BioFarma Research group, University of Santiago de Compostela e-mail: geert.daudey@usc.es EU-OPENSCREEN, and its Spanish node ES-OPENSCREEN, extends an invitation to chemists to contribute proprietary compounds to the Academic Compound Library Initiative. As a premier Research Infrastructure for chemical
- [Adaption of Lumit p-STAT3 Cellular Immunoassay to high-throughput screening format for identification of JAK/STAT pathway antagonists](https://www.sddn.es/poster/adaption-of-lumit-p-stat3-cellular-immunoassay-to-high-throughput-screening-format-for-identification-of-jak-stat-pathway-antagonists/) - Name of Authors: Iván Marcos Name of Institution: Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711 e-mail: ivan.marcos@promega.com Poster Congreso SDDN 2023
- [Discovering a potent NMDA receptor antagonist against Alzheimer’s Disease: from the initial design stage to in vivo testing](https://www.sddn.es/poster/discovering-a-potent-nmda-receptor-antagonist-against-alzheimers-disease-from-the-initial-design-stage-to-in-vivo-testing/) - L. Turcu1, 4, C. Griñán-Ferré2, R. Leiva1, J. Companys-Alemany2, L. León-García3, E. Gratacòs-Batlle4, J. Brea5, M. I. Loza5, F. X. Sureda3, M. Pallàs2, D. Soto4, S. Vázquez1 1 Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències de l’Alimentació and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31,
- [Imidazole-Linked Heterocycles with anti-Alzheimer properties](https://www.sddn.es/poster/imidazole-linked-heterocycles-with-anti-alzheimer-properties/) - Carmen Escolanoa, Carla Barbaracia, Andrea Bagána, Christian Griñán-Ferréb,c, Mercè Pallàsb, José Ángel Morales-Garcíad, José Breae, Mabel Lozae, Caridad Diazf, Rosario Fernández-Godinof, Olga Genilloudf a Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan
- [Novel bicyclic α-iminophosphonate ligands targeting the imidazoline I2 receptor as neuroprotective agents](https://www.sddn.es/poster/novel-bicyclic-α-iminophosphonate-ligands-targeting-the-imidazoline-i2-receptor-as-neuroprotective-agents/) - Carla Barbaracia, Andrea Bagana, Alba Irisarrib, Christian Grinan-Ferrebc, Merce Pallasb, Elies Molinsd, Jose A. Morales-Garciae, Carmen Escolanoa a Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028, Barcelona, Spain; cescolano@ub.edu
- [Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks](https://www.sddn.es/poster/optimizing-drug-design-by-merging-generative-ai-with-active-learning-frameworks/) - Name of Authors: Isaac Filella Name of Institution: Barcelona Supercomputing Center e-mail: isaac.filella1@bsc.es Traditional drug discovery programs are being transformed by the advent of machine learning methods. Among these, Generative AI methods (GM) have gained attention due to their ability to design new molecules and enhance specific properties of existing ones. However, current GM methods
- [Scipion-chem: an open platform for Virtual Drug Screening](https://www.sddn.es/poster/scipion-chem-an-open-platform-for-virtual-drug-screening/) - Name of Authors: D. Del Hoyo, Martin Salinas, Alba Lomas, E. Ulzurrun, N. Campillo, C.O.S. Sorzano Name of Institution: National Center of Biotechnology (CNB-CSIC). Madrid. Spain, Biological Research Center (CIB-CSIC), Madrid, Spain, Institute of Mathematical Sciences (ICMAT-CSIC), Madrid, Spain e-mail: ddelhoyo@cnb.csic.es Virtual Drug Screening (VDS) tackles the problem of Drug Discovery by computationally reducing the
- [New Microbial Natural Products Targets Cancer Stem Cells and Stops Pancreatic Cancer Progression by Inhibiting MEK2-dependent Cell Signaling](https://www.sddn.es/poster/new-microbial-natural-products-targets-cancer-stem-cells-and-stops-pancreatic-cancer-progression-by-inhibiting-mek2-dependent-cell-signaling/) - Carmen Ramos*1, Gloria Crespo 1, Nuria de Pedro 1, Carmen Griñán-Lisón 2, Caridad Díaz 1, Víctor González-Menéndez 1, Juan A. Marchal 2, Rosario Fernández-Godino 1, Olga Genilloud 1 and Fernando Reyes 1. 1Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento 34, 18016 Granada, Spain. 2 Biosanitary Research Institute of Granada (ibs. GRANADA), University Hospitals of Granada-University of Granada, Granada, Spain. Pancreatic cancer shows
- [High Content Screening as a Drug Discovery Platform](https://www.sddn.es/poster/high-content-screening-as-a-drug-discovery-platform/) - Marta Martínez-García, Carmen Ramos, Thomas A. Mackenzie and Rosario Fernández-Godino. Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento 34, 18016 Granada, Spain. High-Content Screening (HCS) technology has revolutionized the early drug discovery field in the last years. HCS combines cell biology and molecular tools with automated high resolution microscopy and robotic handling. This
- [Predictive metabolomics signature of relapse in metastasic colorectal cancer](https://www.sddn.es/poster/predictive-metabolomics-signature-of-relapse-in-metastasic-colorectal-cancer/) - Caridad Díaz1, Carmen González-Olmedo2, Francisco José García-Verdejo2, Patricia Mena1, Leticia Díaz-Beltrán2, José Antonio López-López2, Rosario Fernández-Godino1, Pedro Sánchez-Rovira2 Fundación MEDINA; Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, 18016, Granada (Spain) Unidad de Oncología médica, Hospital Universitario de Jaén, Jaén, 23007 (Spain) Colorectal liver metastasis (CRLM) is the main cause of colorectal cancer
- [Development of a yeast bioassay to screen for Nirmatrelvir drug resistance mutations in the SARS-CoV-2 protease 3CLpro](https://www.sddn.es/poster/development-of-a-yeast-bioassay-to-screen-for-nirmatrelvir-drug-resistance-mutations-in-the-sars-cov-2-protease-3clpro/) - Name of Authors: Óscar Barbero-Úriz, Gema González-Rubio, María Molina, Víctor J. Cid, Teresa Fernández-Acero. Name of Institution: Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid. e-mail: oscaralb@ucm.es, teresafe@ucm.es SARS-CoV-2 is a single-stranded RNA + polarity virus that belongs to coronavirus family. Its genome is organized into 14 ORFs, 2 of which
- [A NEW INDICATION FOR SOLUBLE EPOXIDE HYDROLASE INHIBITORS: DESIGN, SYNTHESIS AND IN VIVO EVALUATION OF NOVEL UREAS IN A MURINE MODEL OF CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN](https://www.sddn.es/poster/a-new-indication-for-soluble-epoxide-hydrolase-inhibitors-design-synthesis-and-in-vivo-evaluation-of-novel-ureas-in-a-murine-model-of-chemotherapy-induced-neuropathic-pain/) - Sandra Codony1, Beatrice Jora1, Miriam Santos-Caballero2, Andreea L. Turcu1, Carla Calvó-Tusell3, Christophe Morisseau4, M. Isabel Loza5, José M. Brea5, Clara Bartra6, Coral Sanfeliu6, Belén Pérez7, Christian Griñán-Ferré8, Mercè Pallàs8, Bruce D. Hammock4, Sílvia Osuna3,9, Ferran Feixas3, Enrique J. Cobos2, Santiago Vázquez1. 1Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia i Ciències
- [Characterization of a model of alopecia areata in C3H/HeJ mice induced by adoptive transfer of lymph node cells](https://www.sddn.es/poster/characterization-of-a-model-of-alopecia-areata-in-c3h-hej-mice-induced-by-adoptive-transfer-of-lymph-node-cells/) - Laura Casals, Elena Calama, Jose Luis Gómez, Jose Luis Montero, Joan Mañé, Christos Kiourtis, Glòria Aniorte, Amadeu Gavaldà Almirall R&D, Barcelona, Spain Alopecia Areata (AA) is an autoimmune disease characterized by acute onset of non-scarring hair loss produced by the damage of hair follicle by T cells. The C3H/HeJ strain of mice spontaneously develops alopecia
- [Good correlation of a murine model of oxazolone-induced chronic dermatitis with major gene hallmarks of atopic dermatitis in human patients](https://www.sddn.es/poster/good-correlation-of-a-murine-model-of-oxazolone-induced-chronic-dermatitis-with-major-gene-hallmarks-of-atopic-dermatitis-in-human-patients/) - Elena Calama, Laura Casals, Fèlix Gil, Arsenio Nueda, Juan Luis Trincado, Amadeu Gavaldà Almirall R&D, Barcelona, Spain Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by pruritus and eczematous skin lesions. It has been described that repeated topical application of oxazolone in the ears of sensitized mice induces lesions that mimic some
- [TRIDs4DEB collaboration: Identification of novel drug discovery starting points for the treatment of recessive dystrophic epidermolysis bullosa](https://www.sddn.es/poster/trids4deb-collaboration-identification-of-novel-drug-discovery-starting-points-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa/) - Irene Jover1, Maria C. Ramos2, María José Escámez3, Estrella Lozoya1, José R. Tormo2, Ángeles Mencía3, Marie-Helene Larraufie1, Cristina Gutierrez1, Fernando Reyes2, Vicente García1, Rosario Cerrato1, Mercè Pont1, Carles Puig1, Miriam Andrés1, Maribel Crespo1, Francisca Vicente2, Nuria Godessart1, Olga Genilloud2, Fernando Larcher3 & Arsenio Nueda1 1 R&D Centre, Almirall S.A., Laureà Miró, 08980 Sant Feliu de
- [MPGI STRATEGY IMPROVES AQUEOUS SOLUBILITY IF COLCHICINE SITE INHIBITORS OF TUBULIN POLYMERIZATION](https://www.sddn.es/poster/mpgi-strategy-improves-aqueous-solubility-if-colchicine-site-inhibitors-of-tubulin-polymerization/) - González1, Y. Ellahioui 1, L. Gallego-Yerga, A. Vicente-Blázquez1,2, R. Álvarez1, M. Medarde1, R. Peláez1. 1 Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain, raquelalvarez@usal.es. 2 Laboratory of Cell Death and Cancer Therapy, Biological Research Center, CSIC, E-28040 Madrid, Spain. Keywords: tubulin, colchicine site, solubility, antimitotic,
- [Stochastic Gate Neural Networks for Automatic Covariate Selection in Pharmacometrics Population Modeling](https://www.sddn.es/poster/stochastic-gate-neural-networks-for-automatic-covariate-selection-in-pharmacometrics-population-modeling/) - Marija Kekic1, Andrzej Nowojewski2, Oleg Stepanov3, Sam Richardson2, Itziar Irurzun3, Diansong Zhou4, Weifeng Tang4, Richard Dearden2 1Imaging & Data Analytics, Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca, Barcelona, Spain 2Imaging & Data Analytics, Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge, UK 3Clinical Pharmacology & Quantitative Pharmacology​, Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge, UK 4Clinical Pharmacology
- [IS IT POSSIBLE TO DEGRADE c-MYC WITH LOW AFFINITY COMPOUND - BASED PROTACs?](https://www.sddn.es/poster/is-it-possible-to-degrade-c-myc-with-low-affinity-compound-based-protacs/) - A. Sánchez-Arfelis1, A. Bertran-Mostazo2, S. Scaffidi2, R. Castaño2, E. Molins3, X. Barril2,4, C. Escolano1, C. Galdeano2 1Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona (UB), Spain. 2Department of Pharmacy, and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, and
- [A NOVEL ALK-BASED COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME](https://www.sddn.es/poster/a-novel-alk-based-combination-therapy-for-the-treatment-of-glioblastoma-multiforme/) - Esther Martínez-Martínez1, Esther Masiá1,2,3, and María J. Vicent1,2,3 1Polymer Therapeutics Lab., 2Screening Platform, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.3Centro de Investigación Biomédica en Red Cáncer (CIBERONC). Glioblastoma multiforme (GBM) is the most frequent class of malignant primary brain tumors and among the most aggressive forms of cancer. Affected individuals present poor prognoses; the
- [LLPS in functional amyloids may unveil novel therapeutic targets for neurodegenerative diseases](https://www.sddn.es/poster/llps-in-functional-amyloids-may-unveil-novel-therapeutic-targets-for-neurodegenerative-diseases/) - Paula López-García, María Eugenia Vaquero, Daniel Ramírez de Mingo, Rubén Hervás, Douglas V. Laurents & Mariano Carrión-Vázquez Liquid-liquid phase separation (LLPS) is a protein condensation process driven by multivalent interactions that promotes the assembly of proteins into membraneless biocondensates. An increasing number of amyloid-forming proteins have been recently found to undergo LLPS, emerging as a
- [Vessel –on-a-chip: advanced in vitro model for cardiovascular research](https://www.sddn.es/poster/vessel-on-a-chip-advanced-in-vitro-model-for-cardiovascular-research/) - Laura Vázquez-Vázquez CSO of BFlow Atherosclerosis is a chronic inflammatory disease of the arterial vessels that is behind the main cardiovascular pathologies. Atherosclerosis is a complex multifactorial process, but the current cell culture models cannot reproduce all physiological conditions of human blood vessels. New in vitro advanced models are needed to test drugs targeting endothelial
- [HARNESSING DRUG METABOLITES IN PRECISION MEDICINE](https://www.sddn.es/poster/harnessing-drug-metabolites-in-precision-medicine/) - Manén1,2, S. Santos1,2, W. Zhang1,2, L. Josa3, C. Serra3, H. Hu4, A. Scrivo2,5, I. Fernández-Carasa2,5, A. Consiglio2,5,6, A. Aytés1,2, M.A. Pujana1,2, A. Llebaria3 , AA. Antolín1,2,4 1 proCURE, Catalan Institute of Oncology (ICO) L'Hospitalet del Llobregat, Barcelona, Spain 2Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain 3 Institute for Advanced Chemistry of Catalonia (IQAC-CSIC),
- [Accelerating drug discovery using Free Energy Perturbation Identification of  potential inhibitors for SARS-Cov-2 cysteine proteases](https://www.sddn.es/poster/accelerating-drug-discovery-using-free-energy-perturbation-identification-of-potential-inhibitors-for-sars-cov-2-cysteine-proteases/) - Sílvia Illa Tuset, Sofia Bariami, Giorgia Zaetta, and Mark Mackey Cresset Discovery experts in Free Energy Perturbation (FEP) methods investigated the binding affinity of compounds with known experimental activity to the Mpro protein, a potential target for SARS-CoV2. Using FEP calculations and applying de novo design expertise to optimize bioisosteric replacement, we generated new designs
- [EFFECTS OF THE SIGMA-2 RECEPTOR ANTAGONIST ADV462 ON COGNITIVE AND MOTIVATIONAL IMPAIRMENT IN THE 5XFAD MOUSE MODEL OF ALZHEIMER’S DISEASE](https://www.sddn.es/poster/effects-of-the-sigma-2-receptor-antagonist-adv462-on-cognitive-and-motivational-impairment-in-the-5xfad-mouse-model-of-alzheimers-disease/) - Manuel MERLOS, Enrique PORTILLO-SALIDO, Beatriz DE LA PUENTE, María PUIGIVILA, Sandra YESTE, Maria Luz ROMERO, Daniel ZAMANILLO, Jose Miguel VELA Welab Barcelona, Parc Científic Barcelona, C/ Baldiri Reixac 4-8, 08028 Barcelona, Spain The sigma-2 receptor (σ2R) has been investigated in the context of cancer treatment and imaging. However, a growing interest in the σ2R as
- [Molecular Modeling for Rational Design and Virtual Screening](https://www.sddn.es/poster/molecular-modeling-for-rational-design-and-virtual-screening/) - Rosalia Pascual, Carmen Almansa, José Miguel Vela Welab Barcelona, Parc Científic Barcelona, C/ Baldiri Reixac 4-8, 08028 Barcelona, Spain WLB-73502 is an internally developed dual σ1 receptor (σ1R) and μ-opioid receptor (MOR) ligand that has been shown in preclinical models to have full antinociceptive efficacy, better neuropathic pain relief and a better safety profile than
- [ADME PROPERTIES AND NON-CLINICAL PHARMACOKINETICS OF A NOVEL SELECTIVE σ2 RECEPTOR LIGAND WITH NEUROPROTECTIVE EFFECTS](https://www.sddn.es/poster/adme-properties-and-non-clinical-pharmacokinetics-of-a-novel-selective-σ2-receptor-ligand-with-neuroprotective-effects/) - Sandra YESTE, Raquel F. REINOSO, MªTeresa SERAFINI, Gregorio ENCINA,Javier COSTEA, Enrique HERNÁNDEZ, Sandra SILVESTRE, Jordi QUINTANA, José Miguel VELA Welab Barcelona, Parc Científic Barcelona, C/ Baldiri Reixac 4-8, 08028 Barcelona, Spain The sigma-2 receptor (S2R) has been investigated in the context of cancer treatment and imaging. However, a growing interest in the S2R as an
- [MedChem approaches to Multimodal Therapy](https://www.sddn.es/poster/medchem-approaches-to-multimodal-therapy/) - Carmen Almansa, José Luís Díaz, Mónica García, Adriana Port, José Miguel Vela Welab Barcelona, Parc Científic Barcelona, C/ Baldiri Reixac 4-8, 08028 Barcelona, Spain Many pathological states are multimodal in nature involving several molecular mechanisms and monomodal therapies often fail to provide complete relief or show undesirable side effects. Multimodal Therapy may be a way
- [EU-OPENSCREEN: Discovery and development of novel chemical probes within an international, collaborative research infrastructure consortium](https://www.sddn.es/poster/4498/) - EU-OPENSCREEN: Discovery and development of novel chemical probes within an international, collaborative research infrastructure consortium

## Webinars

- [How and when to protect Drug Discoveries (DDs) through patents. Dialogue with Q&A between a researcher in DD and a patent attorney](https://www.sddn.es/webinar/how-and-when-to-protect-drug-discoveries-dds-through-patents-dialogue-with-qa-between-a-researcher-in-dd-and-a-patent-attorney/) - Fecha: Miércoles 27 de mayo, 16:00 -17:00 Ponentes: Manuel Illescas, socio director de MIAPatents, y José Manuel González, asociado en MIAPatents Sobre el webinar: Este webinar, impartido por Manuel Illescas (Managing Partner, MIAPatents) y José Manuel González (Associate, MIAPatents), se centrará en cómo proteger mediante patente moléculas identificadas en programas de descubrimiento de fármacos. La
- [Giving Old Compounds a New Life in Drug Discovery: The Spanish Public Chemical Library (QPE) and EU-Openscreen](https://www.sddn.es/webinar/giving-old-compounds-a-new-life-in-drug-discovery-the-spanish-public-chemical-library-cpe-and-eu-openscreen/) - Fecha: Martes 21 de abril, 16:00 -17:00 Ponente: Antonio Gómez, Director Public-Private Partnerships, Kaertor Foundation Sobre el webinar: Este webinar, presentado por Antonio Gómez, Director de Public-Private Partnerships en la Fundación Kaertor, explorará cómo los compuestos químicos existentes se están reutilizando para acelerar el descubrimiento de fármacos a través de la Biblioteca Química Pública Española
- [Unleashing Functional Genomics for Novel Therapeutic Discovery: Navigating Scale and Complexity](https://www.sddn.es/webinar/unleashing-functional-genomics-for-novel-therapeutic-discovery-navigating-scale-and-complexity/) - Fecha: Jueves 5 de marzo, 16:00 -17:00 Ponente: Leire Escudero-Ibarz, Associate Director, Center for Genomics Research, AstraZeneca Sobre el webinar: Este seminario web explorará cómo la genómica funcional está impulsando el descubrimiento de nuevas dianas terapéuticas en un entorno definido por el crecimiento exponencial de los datos y una complejidad tecnológica cada vez mayor. Leire
- [Challenges Faced in Establishing a Drug Discovery Startup](https://www.sddn.es/webinar/challenges_establishing_startup/) - Fecha: Martes 16 de diciembre, 16:00 - 17:00 Ponente: Ana Bouchet, PhD (Co-Founder Lifesome Therapeutics) Sobre el webinar: Ana Bouchet compartirá su experiencia en la traducción de descubrimientos fundamentales en biofísica de membranas a innovaciones terapéuticas. Analizará los pasos científicos y estratégicos clave que llevaron a la creación de Lifesome Therapeutics, destacando los retos a
- [From Science to Success: Why Strong Research Isn’t Enough in Early Biotech Development](https://www.sddn.es/webinar/from-science-to-success-why-strong-research-isnt-enough-in-early-biotech-development/) - Fecha: Jueves 25 de septiembre, 16:00 - 17:00 Ponente: Ignacio Sancho-Martinez, PhD (CEO & Managing Partner en INBISTRA) Sobre el webinar: Este seminario web explora la transición crítica del pensamiento centrado en la investigación al desarrollo de programas, abarcando la gestión de portafolio, la valoración de activos, la recaudación de fondos de capital de riesgo
- [From Complexity to Clarity: Smarter Data Management for Chemicals, Biologicals & Assays](https://www.sddn.es/webinar/from-complexity-to-clarity-smarter-data-management-for-chemicals-biologicals-assays/) - Fecha: Jueves 27 de marzo, 16:00 - 17:00 Ponente: Dr. Susana Tomasio, CDD Vault Sobre el webinar: En un entorno en el que la gestión eficiente de los datos científicos es esencial para la innovación, este seminario web explorará estrategias avanzadas para optimizar el manejo de la información relacionada con productos químicos, biológicos y ensayos.
- [Ayudas e instrumentos a nivel nacional e internacional en Salud de CDTI y Horizonte Europa](https://www.sddn.es/webinar/ayudas-e-instrumentos-a-nivel-nacional-e-internacional-en-salud-de-cdti-y-horizonte-europa/) - No te pierdas nuestro último webinar sobre las Ayudas e instrumentos a nivel nacional e internacional en salud de CDTI y Horizonte Europa. ¡Regístrate ya!
- [A harmonized workflow for functional genomic screening using cell painting](https://www.sddn.es/webinar/a-harmonized-workflow-for-functional-genomic-screening-using-cell-painting/) - SDDN is the Spanish Drug Discovery Network. You can't miss our next webinar! Our speakers are Barbara Sonnenberg and Alexander Schreiner, from Revvity
- [The new wave of label-free interaction analysis for drug discovery](https://www.sddn.es/webinar/the-new-wave-of-label-free-interaction-analysis-for-drug-discovery/) - Fecha: 19 de Septiembre de 2024 Ponente: Ph.D. Andrea Zapater Moros Link para registrar en el webinar: ¡No te lo pierdas! El próximo jueves 19 de septiembre, la doctora Andrea Zapater Moros, especialista en productos BIO de Paralab Bio SL, profundizará en las últimas técnicas de análisis de interacciones sin etiquetas y su profundo impacto
- [New trends in open innovation: an Almirall perspective](https://www.sddn.es/webinar/new-trends-in-open-innovation-an-almirall-perspective/) - Fecha: Junio 18, 16:00 – 17:00 Ponente: Maribel Crespo (Almirall) Link para registrar en el webinar: Haga clic aquí para unirse a la reunión Sobre Maribel: Maribel Crespo es Doctora Ingeniera Química por el Instituto Químico de Sarrià (Barcelona). Se incorporó a Almirall como Química Medicinal liderando varios proyectos de Drug Discovery. Desde 2011 gestiona
- [Innovating Discovery: Promega's Technologies for Assay Development and High-Throughput Screening](https://www.sddn.es/webinar/innovating-discovery-promegas-technologies-for-assay-development-and-high-throughput-screening/) - Martes 2 de abril de 2024 De 16:00 a 17:00 Ponente: Julie Conkright-Finchman (Directora de Colaboraciones Estratégicas de Promega Biotech Ibérica S.L.) Revive el webinar en el siguiente enlace: urldefense.com

## Events

- [XVIII SDDN Meeting 2026](https://www.sddn.es/event/xviii-sddn-meeting-2026/) - Partners and sponsors should enter the discount code provided by SDDN during the final step of the registration process. If you experience any issues, please contact us at sddn2026@sddn.es.
- [XV SDDN Meeting Barcelona 2023](https://www.sddn.es/event/xv-sddn-meeting-barcelona-2023/) - *All attendees to the XV SDDN meeting in Barcelona. If you choose the category "Early career professional" (i.e. have completed undergraduate and/or graduate school and are within the first five years of their professional career) / Student (i.e. currently enrolled in full-time graduate or undergraduate studies), you must accredit your eligibility by sending a certificate from your educative institution or a letter from your supervisor. Once validated by the organization, your place at the congress will be confirmed.
- [XIV SDDN Meeting Granada 2022](https://www.sddn.es/event/xiv-sddn-meeting-granada-2022/) - *All attendees to the XIV SDDN meeting in Granada, will automatically join as members of SDDN until August 31st, 2023. If you choose the category "Early career professional" (i.e. have completed undergraduate and/or graduate school and are within the first five years of their professional career) / Student (i.e. currently enrolled in full-time graduate or undergraduate studies), you must accredit your eligibility by sending a certificate from your educative institution or a letter from your supervisor. Once validated by the organization, your place at the congress will be confirmed.

## Event Attendees

- [Gaelle Zighelboim Cavassa](https://www.sddn.es/mep_events_attendees/gaelle-zighelboim-cavassa/)
- [Maria João Matos](https://www.sddn.es/mep_events_attendees/maria-joao-matos/)
- [Ángela Arnosa](https://www.sddn.es/mep_events_attendees/angela-arnosa-4/)
- [Ángela Arnosa](https://www.sddn.es/mep_events_attendees/angela-arnosa-3/)
- [Ángela Arnosa](https://www.sddn.es/mep_events_attendees/angela-arnosa-2/)
- [Ángela Arnosa](https://www.sddn.es/mep_events_attendees/angela-arnosa/)
- [Ángela Arnosa Prieto](https://www.sddn.es/mep_events_attendees/angela-arnosa-prieto/)
- [CARLOS SIALER](https://www.sddn.es/mep_events_attendees/carlos-sialer/)
- [Jessica Griffiths](https://www.sddn.es/mep_events_attendees/jessica-griffiths/)
- [Guillermo Rodríguez Lázaro](https://www.sddn.es/mep_events_attendees/guillermo-rodrguez-lzaro/)
- [Juan Carlos Morales](https://www.sddn.es/mep_events_attendees/juan-carlos-morales/)
- [Jose Maria Perez Victoria](https://www.sddn.es/mep_events_attendees/jose-maria-perez-victoria/)
- [Graciela Juez Castillo](https://www.sddn.es/mep_events_attendees/graciela-juez-castillo/)
- [Benedetta Montagnini](https://www.sddn.es/mep_events_attendees/benedetta-montagnini/)
- [Benedetta Montagnini](https://www.sddn.es/mep_events_attendees/benedetta-montagnini-3/)
- [Nicolò Sacchetti](https://www.sddn.es/mep_events_attendees/nicol-sacchetti/)
- [Victoria Vila del Castillo](https://www.sddn.es/mep_events_attendees/victoria-vila-del-castillo/)
- [Lucia Giraldo](https://www.sddn.es/mep_events_attendees/lucia-giraldo/)
- [Ignacio Fernandez Pastor](https://www.sddn.es/mep_events_attendees/ignacio-fernandez-pastor/)
- [Jose Manuel Monje Moreno](https://www.sddn.es/mep_events_attendees/jose-manuel-monje-moreno/)
- [Raúl Martín-Ruiz](https://www.sddn.es/mep_events_attendees/ral-martn-ruiz/)
- [José Alberto Villamor](https://www.sddn.es/mep_events_attendees/jos-alberto-villamor/)
- [Òscar Mateu Sánchez](https://www.sddn.es/mep_events_attendees/scar-mateu-snchez/)
- [Enrique Neumann](https://www.sddn.es/mep_events_attendees/enrique-neumann/)
- [Juan Ortega Vidal](https://www.sddn.es/mep_events_attendees/juan-ortega-vidal/)
- [Juan Ortega Vidal](https://www.sddn.es/mep_events_attendees/juan-ortega-vidal-2/)
- [María J. Vicent](https://www.sddn.es/mep_events_attendees/mara-j-vicent/)
- [Ignacio Castilla Maldonado](https://www.sddn.es/mep_events_attendees/ignacio-castilla-maldonado/)
- [María Mar Orzáez Calatayud](https://www.sddn.es/mep_events_attendees/mara-mar-orzez-calatayud/)
- [Fernando Martin Garcia](https://www.sddn.es/mep_events_attendees/fernando-martin-garcia/)
- [Linos Lazarides](https://www.sddn.es/mep_events_attendees/linos-lazarides/)
- [María José Resina Rueda](https://www.sddn.es/mep_events_attendees/mara-jos-resina-rueda/)
- [PABLO ANTEQUERA PARRILLA](https://www.sddn.es/mep_events_attendees/pablo-antequera-parrilla/)
- [Shannon Amy Jenkins](https://www.sddn.es/mep_events_attendees/shannon-amy-jenkins/)
- [Santiago Pérez Rodríguez](https://www.sddn.es/mep_events_attendees/santiago-prez-rodrguez/)
- [MARIA ISABEL LOZA GARCIA](https://www.sddn.es/mep_events_attendees/maria-isabel-loza-garcia/)
- [Carme Pampin Casal](https://www.sddn.es/mep_events_attendees/carme-pampin-casal/)
- [José Pérez del Palacio](https://www.sddn.es/mep_events_attendees/jos-prez-del-palacio/)
- [MERCEDES DE LA CRUZ](https://www.sddn.es/mep_events_attendees/mercedes-de-la-cruz/)
- [DOLORES GONZÁLEZ PACANOWSKA](https://www.sddn.es/mep_events_attendees/dolores-gonzlez-pacanowska/)
- [Carlos Cordón Obras](https://www.sddn.es/mep_events_attendees/carlos-cordn-obras/)
- [CRISTINA BOSCH NAVARRETE](https://www.sddn.es/mep_events_attendees/cristina-bosch-navarrete/)
- [GUIOMAR PÉREZ MORENO](https://www.sddn.es/mep_events_attendees/guiomar-prez-moreno-2/)
- [GUIOMAR PÉREZ MORENO](https://www.sddn.es/mep_events_attendees/guiomar-prez-moreno/)
- [BLANCA MARTINEZ ARRIBAS](https://www.sddn.es/mep_events_attendees/blanca-martinez-arribas/)
- [ROSARIO DÍAZ GONZÁLEZ](https://www.sddn.es/mep_events_attendees/rosario-daz-gonzlez/)
- [Geert Daudey](https://www.sddn.es/mep_events_attendees/geert-daudey/)
- [Israel Ramos](https://www.sddn.es/mep_events_attendees/israel-ramos/)
- [Maksym Vaskin](https://www.sddn.es/mep_events_attendees/maksym-vaskin/)
- [María Caballero](https://www.sddn.es/mep_events_attendees/mara-caballero/)
- [Carmen Gil](https://www.sddn.es/mep_events_attendees/carmen-gil/)
- [Ana Martinez](https://www.sddn.es/mep_events_attendees/ana-martinez/)
- [José Murillo Alba](https://www.sddn.es/mep_events_attendees/jos-murillo-alba/)
- [Marina Sánchez Hidalgo](https://www.sddn.es/mep_events_attendees/marina-snchez-hidalgo/)
- [Elena Torres](https://www.sddn.es/mep_events_attendees/elena-torres/)
- [Francisco Javier Ortiz López](https://www.sddn.es/mep_events_attendees/francisco-javier-ortiz-lpez/)
- [Alex Gómez Garrido](https://www.sddn.es/mep_events_attendees/alex-gmez-garrido/)
- [Ignacio Ibáñez Rodríguez](https://www.sddn.es/mep_events_attendees/ignacio-ibez-rodrguez/)
- [Ana Belén Díaz Ruano](https://www.sddn.es/mep_events_attendees/ana-beln-daz-ruano/)
- [Damaso MOLERO SANCHEZ](https://www.sddn.es/mep_events_attendees/damaso-molero-sanchez/)
- [Rubén Cebrián Castillo](https://www.sddn.es/mep_events_attendees/rubn-cebrin-castillo/)
- [ALBERTO RUEDA LEON](https://www.sddn.es/mep_events_attendees/alberto-rueda-leon/)
- [Brunella](https://www.sddn.es/mep_events_attendees/brunella/)
- [Julian Francisco Fernandez](https://www.sddn.es/mep_events_attendees/julian-francisco-fernandez/)
- [Sergio Sopeña de Frutos](https://www.sddn.es/mep_events_attendees/sergio-sopea-de-frutos/)
- [ELENA RIVAS PEREZ](https://www.sddn.es/mep_events_attendees/elena-rivas-perez/)
- [ANTONIO QUÍLEZ ÁLVAREZ](https://www.sddn.es/mep_events_attendees/antonio-qulez-lvarez/)
- [MARIA GUERRA GARCIA](https://www.sddn.es/mep_events_attendees/maria-guerra-garcia/)
- [Óscar Alberto Barbero Úriz](https://www.sddn.es/mep_events_attendees/scar-alberto-barbero-riz/)
- [TERESA FERNÁNDEZ-ACERO BASCONES](https://www.sddn.es/mep_events_attendees/teresa-fernndez-acero-bascones/)
- [Caridad Díaz Navarro](https://www.sddn.es/mep_events_attendees/caridad-daz-navarro/)
- [José A García-Salcedo](https://www.sddn.es/mep_events_attendees/jos-a-garca-salcedo/)
- [Matilde Ortiz González](https://www.sddn.es/mep_events_attendees/matilde-ortiz-gonzlez/)
- [Mercedes Perez-Bonilla](https://www.sddn.es/mep_events_attendees/mercedes-perez-bonilla/)
- [José Pérez del Palacio](https://www.sddn.es/mep_events_attendees/jos-prez-del-palacio-2/)
- [Manuel Picon Ruiz](https://www.sddn.es/mep_events_attendees/manuel-picon-ruiz/)
- [María del Pilar](https://www.sddn.es/mep_events_attendees/mara-del-pilar/)
- [Paula López García](https://www.sddn.es/mep_events_attendees/paula-lpez-garca/)
- [Maria Majellaro](https://www.sddn.es/mep_events_attendees/maria-majellaro/)
- [JYOTSNA AMBURE](https://www.sddn.es/mep_events_attendees/jyotsna-ambure/)
- [Esther Masiá Sanchis](https://www.sddn.es/mep_events_attendees/esther-masi-sanchis/)
- [Jordi Quintana](https://www.sddn.es/mep_events_attendees/jordi-quintana/)
- [Elizabeth Domingo Contreras](https://www.sddn.es/mep_events_attendees/elizabeth-domingo-contreras/)
- [Noelia López Montero](https://www.sddn.es/mep_events_attendees/noelia-lpez-montero/)
- [Thomas Andrew Mackenzie](https://www.sddn.es/mep_events_attendees/thomas-andrew-mackenzie/)
- [Fernando Reyes](https://www.sddn.es/mep_events_attendees/fernando-reyes/)
- [Rodrigo Gajardo Rodríguez](https://www.sddn.es/mep_events_attendees/rodrigo-gajardo-rodrguez/)
- [FRANCISCO JOSÉ CASTILLO CORREA](https://www.sddn.es/mep_events_attendees/francisco-jos-castillo-correa/)
- [Carmen Ramos](https://www.sddn.es/mep_events_attendees/carmen-ramos/)
- [IGNACIO GONZALEZ MARTINEZ](https://www.sddn.es/mep_events_attendees/ignacio-gonzalez-martinez/)
- [Rubén Málaga](https://www.sddn.es/mep_events_attendees/rubn-mlaga/)
- [Marta Martínez García](https://www.sddn.es/mep_events_attendees/marta-martnez-garca/)
- [Mouli Chakraborty](https://www.sddn.es/mep_events_attendees/mouli-chakraborty/)
- [Matilde Fernández Rodríguez](https://www.sddn.es/mep_events_attendees/matilde-fernndez-rodrguez/)
- [Manuel Montalbán López](https://www.sddn.es/mep_events_attendees/manuel-montalbn-lpez/)
- [Maria Jurado Pueyo](https://www.sddn.es/mep_events_attendees/maria-jurado-pueyo-3/)
- [Maria Jurado Pueyo](https://www.sddn.es/mep_events_attendees/maria-jurado-pueyo-2/)
- [Maria Jurado Pueyo](https://www.sddn.es/mep_events_attendees/maria-jurado-pueyo/)
- [Gijs Jochems](https://www.sddn.es/mep_events_attendees/gijs-jochems/)
- [Javier](https://www.sddn.es/mep_events_attendees/javier/)
- [Claus Møller](https://www.sddn.es/mep_events_attendees/claus-mller/)
- [Mano Manoharan](https://www.sddn.es/mep_events_attendees/mano-manoharan/)
- [Sergio Lociuro](https://www.sddn.es/mep_events_attendees/sergio-lociuro/)
- [MARTA ISASA](https://www.sddn.es/mep_events_attendees/marta-isasa/)
- [Jordi Gracia](https://www.sddn.es/mep_events_attendees/jordi-gracia/)
- [Thomas Eichholtz](https://www.sddn.es/mep_events_attendees/thomas-eichholtz/)
- [Francesc Mitjans](https://www.sddn.es/mep_events_attendees/francesc-mitjans/)
- [Rafael Cantón](https://www.sddn.es/mep_events_attendees/rafael-cantn/)
- [Damia Tormo](https://www.sddn.es/mep_events_attendees/damia-tormo/)
- [CARLES GALDEANO](https://www.sddn.es/mep_events_attendees/carles-galdeano/)
- [Tamara Martínez](https://www.sddn.es/mep_events_attendees/tamara-martnez/)
- [Marie Hélène Larraufie](https://www.sddn.es/mep_events_attendees/marie-hlne-larraufie/)
- [David Zollman](https://www.sddn.es/mep_events_attendees/david-zollman/)
- [Luis Álvarez Valina](https://www.sddn.es/mep_events_attendees/luis-lvarez-valina/)
- [Concepción González Bello](https://www.sddn.es/mep_events_attendees/concepcin-gonzlez-bello/)
- [Jorge Beleta](https://www.sddn.es/mep_events_attendees/jorge-beleta-2/)
- [Beenat Crosas](https://www.sddn.es/mep_events_attendees/beenat-crosas/)
- [Domingo Gargallo-Viola](https://www.sddn.es/mep_events_attendees/domingo-gargallo-viola/)
- [María Beatriz LLamusi Troisi](https://www.sddn.es/mep_events_attendees/mara-beatriz-llamusi-troisi/)
- [Miguel Moreno Molina](https://www.sddn.es/mep_events_attendees/miguel-moreno-molina/)
- [Ricardo Palacios Urtasun](https://www.sddn.es/mep_events_attendees/ricardo-palacios-urtasun/)
- [Santiago Vázquez](https://www.sddn.es/mep_events_attendees/santiago-vzquez/)
- [Frederick Annang](https://www.sddn.es/mep_events_attendees/frederick-annang/)
- [Teresa Sardon Urtiaga](https://www.sddn.es/mep_events_attendees/teresa-sardon-urtiaga/)
- [JOSE JULIO MARTIN PLAZA](https://www.sddn.es/mep_events_attendees/jose-julio-martin-plaza/)
- [MARIA TERESA DOMENECH MARTINEZ](https://www.sddn.es/mep_events_attendees/maria-teresa-domenech-martinez/)
- [MIRIAM ANDRES MARTINEZ](https://www.sddn.es/mep_events_attendees/miriam-andres-martinez/)
- [ARSENIO NUEDA](https://www.sddn.es/mep_events_attendees/arsenio-nueda/)
- [Mario Antonazzo Soler](https://www.sddn.es/mep_events_attendees/mario-antonazzo-soler/)
- [Daniel Zabala Alvarez](https://www.sddn.es/mep_events_attendees/daniel-zabala-alvarez/)
- [Jorge Beleta](https://www.sddn.es/mep_events_attendees/jorge-beleta/)
- [Xavier Codony Soler](https://www.sddn.es/mep_events_attendees/xavier-codony-soler-3/)
- [José Miguel Vela](https://www.sddn.es/mep_events_attendees/jos-miguel-vela/)
- [Piotr Konieczny](https://www.sddn.es/mep_events_attendees/piotr-konieczny/)
- [Cristina Gómez de la Oliva](https://www.sddn.es/mep_events_attendees/cristina-gmez-de-la-oliva/)
- [ELENA HERNÁNDEZ ENCINAS](https://www.sddn.es/mep_events_attendees/elena-hernndez-encinas/)
- [Elena Gómez-Casero](https://www.sddn.es/mep_events_attendees/elena-gmez-casero/)
- [Ana Belén García](https://www.sddn.es/mep_events_attendees/ana-beln-garca/)
- [Fernando J Montero](https://www.sddn.es/mep_events_attendees/fernando-j-montero/)
- [Marcos Engroba](https://www.sddn.es/mep_events_attendees/marcos-engroba/)
- [Jose Carlos González](https://www.sddn.es/mep_events_attendees/jose-carlos-gonzlez/)
- [María Eugenia Pachón Ibáñez](https://www.sddn.es/mep_events_attendees/mara-eugenia-pachn-ibez/)
- [Benedetta Montagnini](https://www.sddn.es/mep_events_attendees/benedetta-montagnini-2/)
- [Rubén Tormo](https://www.sddn.es/mep_events_attendees/rubn-tormo/)
- [Marisa](https://www.sddn.es/mep_events_attendees/marisa/)
- [Xavier Codony Soler](https://www.sddn.es/mep_events_attendees/xavier-codony-soler/)
- [Xavier Codony Soler](https://www.sddn.es/mep_events_attendees/xavier-codony-soler-2/)
- [Emilio Diez Monedero](https://www.sddn.es/mep_events_attendees/emilio-diez-monedero/)
- [Matilde Lopez Freire](https://www.sddn.es/mep_events_attendees/matilde-lopez-freire/)
- [ROSARIO FERNÁNDEZ GODINO](https://www.sddn.es/mep_events_attendees/rosario-fernndez-godino/)
- [Concepción Marañón](https://www.sddn.es/mep_events_attendees/concepcin-maran/)
- [Olga Genilloud](https://www.sddn.es/mep_events_attendees/olga-genilloud/)

## Global Reg Form

- [Attendee event form](https://www.sddn.es/mep_events_reg_form/attendee-event-form/)
- [R](https://www.sddn.es/mep_events_reg_form/r/)

## TF Header - Footer Template

- [XIV SDDN Meeting](https://www.sddn.es/tf_header_footer/xiv-sddn-meeting-2/)
- [Menu Principal](https://www.sddn.es/tf_header_footer/xiv-sddn-meeting/)

## Categories

- [Sin categoría](https://www.sddn.es/category/sin-categoria/)

## Product categories

- [Sin categorizar](https://www.sddn.es/categoria-producto/sin-categorizar/)

## Events Category

- [Granada](https://www.sddn.es/mep_cat/granada/)
- [Barcelona](https://www.sddn.es/mep_cat/barcelona/)
- [Pamplona](https://www.sddn.es/mep_cat/pamplona/)

## Events Organizer

- [SDDN Association and Fundación MEDINA](https://www.sddn.es/mep_org/sddn-association-and-fundacion-medina/)